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iv 
Abstract 
 
 Apoptosis is a form of controlled cell death that is important to tissue homeostasis. There 
are a variety of pro- and anti-apoptotic proteins that play an important role in the regulation of cell 
death. Apoptosis repressor with caspase recruitment domain (ARC) is a potent anti-apoptotic 
protein that has the ability to inhibit cell death through all the major apoptotic pathways. ARC is 
highly expressed in post-mitotic tissue such as cardiac muscle, neurons, and skeletal muscle, but 
is expressed at much lower levels in other tissues. However, ARC protein levels can increase 
dramatically when some tissues become cancerous. Research has shown that this increase in ARC 
protein content results in resistance to chemotherapeutic drugs. Additionally, decreasing ARC 
protein in cancer cell lines has been shown to be effective in increasing the sensitivity of these 
cancer cells to apoptosis-inducing agents. Therefore, ARC presents an attractive therapeutic target. 
The development of a reporter system that is driven by the ARC promoter region would allow for 
the monitoring of ARC expression during a high-throughput drug screen. Green fluorescent protein 
(GFP) is a valuable tool commonly used to analyse gene expression in cells and presents numerous 
advantages over a luciferase-based reporter system. First, GFP can be detected without the lysing 
the cells and without the addition of costly substrates. Second, fluorescence can be detected by a 
simple plate reader assay. Thus, a GFP reporter plasmid under the control of the ARC promoter 
region was developed. However, GFP production was limited in cells transfected with the reporter 
plasmid and significant changes in GFP fluorescence as ARC protein levels increased was not 
detected by the fluorescent plate reader assay. Ultimately, more research is needed to develop a 
reporter plasmid that responds to ARC promoter activation and can be detected by a plate reader 
assay.  
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1 
Introduction  
	
1 Apoptosis 
Apoptosis is a form of controlled cell death that is required for the maintenance of tissue 
homeostasis (1). It is a highly conserved process critical in the formation of tissue during 
development and throughout tissue remodelling (2). Additionally, apoptosis plays an important 
role in ensuring that damaged or mutated cells are eliminated and therefore prevented from causing 
further harm (2). When a cell is highly stressed, such as when DNA damage occurs or following 
growth factor depletion, apoptotic signalling pathways may be activated (3). In general, these 
pathways ultimately converge onto pro-apoptotic proteolytic enzymes known as caspases, 
resulting in the degradation of cellular proteins and ultimately cell death without a large 
inflammatory immune response (3,4). The different apoptotic signalling pathways involve distinct 
components of the cell (5).  
1.1 The intrinsic pathway  
Mitochondria play an integral role in the intrinsic apoptotic signalling pathway, which 
involves the release of pro-apoptotic proteins (6). The release of these proteins occurs as a result 
of mitochondrial outer membrane permeabilization (MOMP) (7).  
The B-cell lymphoma 2 (BCL-2) family of proteins play an important role in the execution 
of cell death through the mitochondria (8). BCL-2 proteins are divided into 3 categories: 
pro-apoptotic, anti-apoptotic, and BCL-2 homology 3-only (BH3-only) (9). The pro-apoptotic 
proteins BCL-2 associated x protein (BAX) and BCL-2 antagonist killer (BAK) are directly 
responsible for the execution of cell death through the creation of a BAX/BAK pore in the outer 
mitochondrial membrane (OMM), which allows for the release of mitochondrial proteins (10). 
Anti-apoptotic proteins, such as B-cell lymphoma-extra large (BCL-XL) and BCL-2, bind to 
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pro-apoptotic factors to prevent them from initiating cell death under normal conditions (11). 
While the exact roles of BH3-only proteins are still under investigation, it is clear that they act as 
critical regulators in the intrinsic apoptotic response by directly activating the pro-apoptotic 
proteins BAX and BAK or by binding to anti-apoptotic proteins to inhibit their ability to prevent 
apoptosis (12–15).  
When an apoptotic signalling pathway is activated, BH3-only proteins are produced and 
directed to execute their particular role, whether that is to displace the anti-apoptotic proteins 
bound to BAX and BAK, bind to free anti-apoptotic proteins to neutralize their effect, or directly 
activate BAX and BAK (16). BAX is a cytosolic protein under normal conditions, but once BAX 
is activated, it translocates to the mitochondria, inserts into the OMM, oligomerizes with other 
BAX molecules, and creates a pore (17). Similarly, BAK, which resides on the mitochondrial 
membrane, oligomerizes with other BAK molecules when it is activated to create a pore in the 
OMM (17).  
Mitochondrial fission and its associated protein Drp-1 have also been shown to be involved 
in apoptosis (18). While there appears to be a relationship between mitochondrial fission and 
MOMP, the details remain unclear (18). However, there is evidence to suggest that Drp-1 
translocates from the cytosol to the mitochondrial membrane with the help of p53 upregulated 
modulator of apoptosis (PUMA) when an apoptotic stimulus is received (19). This results in the 
fragmentation of mitochondria and may lead to the release of pro-apoptotic proteins (18,19). 
The pore created in the OMM allows for the release of pro-apoptotic proteins such as 
cytochrome c, apoptosis-inducing factor (AIF), endonuclease G (Endo G), and second 
mitochondria-derived activator of caspases (SMAC) (20). These proteins play an important role 
in cell function while located in the mitochondria, but each protein plays a different role in the 
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execution of cell death when they are released into the cytosol (21). Cytochrome c combines with 
apoptotic protease activating factor 1 (Apaf-1) and the initiator caspase, caspase-9, with the help 
of dATP to create the apoptosome (22). The apoptosome activates the executioner caspase 
caspase-3, which leads to protein degradation and cell death (23). Additionally, the release of 
cytochrome c causes dysfunction of the electron transport chain, leading to a decrease in ATP 
and an increase in free radical production, which also contributes to the death of the cell (24,25). 
When released from the mitochondria, AIF and Endo G translocate to the nucleus and cause 
DNA fragmentation, an important component of the cell death process (26,27). AIF and Endo G 
can also be released from the mitochondria independent of caspase activation to induce cell 
death (26,27). Furthermore, SMAC acts as an antagonist of X-linked inhibitor of apoptosis 
protein (XIAP) and other inhibitor of apoptosis proteins (IAPs) to block their anti-apoptotic 
function (28). Overall, these mitochondrial proteins play a critical role in the execution of cell 
death through the intrinsic pathway.  
1.2 The extrinsic pathway 
The extrinsic apoptotic signalling pathway is reliant on the binding of ligands, including Fas, 
tumour necrosis factor (TNF) and TNF-related apoptosis-inducing ligand (TRAIL), to cell 
surface death receptors (29). The binding of the specific ligand to the appropriate receptor results 
in death receptor activation and recruitment of the associated adaptor protein, including Fas 
associated protein with death domain (FADD) and tumour necrosis factor receptor 
type 1-associated death domain (TRADD) (29). TRADD/FADD attach to the death receptor 
through the binding of the death domains (DD), which are located on the cytosolic portion of the 
death receptor (29,30). Procaspase-8, an initiator caspase, binds to FADD through the death 
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effector domains (DED) located on both proteins (29,30). This forms the death inducing 
signalling complex (DISC) and leads to the activation of caspase-8 (Figure 1) (30).  
 
 
Activated caspase-8 can cleave the BH3-only protein BID to form truncated BID (tBID), 
which translocates to the mitochondria, activates the intrinsic pathway, and ultimately amplifies 
the apoptotic signal received through the death receptor (31). Independent of the intrinsic 
pathway, caspase-8 can directly activate caspase-3, which will lead to cell degradation (32).  
1.3 The endoplasmic reticulum stress pathway 
The accumulation of unfolded proteins in the endoplasmic reticulum (ER) can create a 
stressful cellular environment and cause calcium to be released into the cytosol (33). If high 
cytosolic calcium levels are maintained, cell death can be initiated by activation of the cysteine 
protease m-calpain (34). Furthermore, caspase-12 may be activated directly by ER stress through 
the dissociation from its adaptor protein at the ER membrane or activated by m-calpain (35,36). 
Activated caspase-12 can activate both caspase-9 and caspase-3, which will lead to cell 
death (37–39). Additionally, the expression of the transcription factor C/EBP homologous 
protein (CHOP) is induced during times of ER stress (40). CHOP may act to as a transcription 
Figure 1: The death inducing signalling complex. Adapted 
from Nam et al., 2004 (30). 
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factor to alter the expression of anti- or pro-apoptotic genes, disrupt the cellular redox state by 
affecting glutathione production, or play a role in protein-protein interactions to cease cell 
proliferation (41).  
In addition to its other functions, mitochondria play an important role in cellular calcium 
regulation in some cells (42). Mitochondria have the ability to sequester cytosolic calcium and 
therefore aid in controlling cytosolic calcium levels (43). However, if the amount of calcium 
sequestered exceeds the amount that the mitochondria can tolerate, the permeability transition 
pore (PTP) may open (43,44). The PTP is created by the voltage dependent anion channel 
(VDAC) on the outer mitochondrial membrane and adenine nucleotide translocase (ANT) on the 
inner mitochondrial membrane, which associates with cyclophilin-D (CyP-D) (45). The 
assembly and opening of this complex can cause a disruption of the mitochondrial membrane 
potential, the release of pro-apoptotic proteins into the cytosol, and subsequent cell death through 
the intrinsic pathway (45). 
1.4 The DNA damage pathway  
DNA damage can result in cell death through the activation of the tumour suppressor 
p53 (46). Activated p53 acts as a transcription factor in the nucleus and promotes the transcription 
of pro-apoptotic and BH3-only proteins such as BAX and PUMA, which can ultimately lead to 
cell death through the intrinsic apoptotic pathway (47,48). Additionally, p53 can lead to the 
production of p53-induced protein with a death domain (PIDD), which can interact with 
receptor-interacting protein (RIP)-associated ICH-1/CED-3 homologous protein with a death 
domain (RAIDD) and caspase-2 (49,50). The interaction of these proteins results in the 
production of the PIDDosome, which activates caspase-2 (51,52). Activated caspase-2 can cleave 
the BH3-only protein BID to form tBID, which can activate the intrinsic apoptotic pathway 
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(50,53). Independent of its transcription factor role, cytosolic p53 has been shown to directly 
activate BAX and BAK, while inhibiting BCL-2 and BCL-XL (54).  
 
2 Apoptosis Repressor with Caspase Recruitment Domain  
Apoptosis repressor with caspase recruitment domain (ARC) is a unique and potent 
anti-apoptotic protein (55,56). The human ARC (NOL3) gene is located on chromosome 16 and 
produces a 208 amino acid protein with a molecular mass of 22.6 kD (56). While most other 
anti-apoptotic proteins appear to have a particular role in a specific apoptotic pathway, it has been 
shown that ARC has the ability to inhibit cell death through all the major apoptotic pathways (56). 
2.1 Function 
ARC consists of two domains that are integral to its function: a caspase recruitment domain 
(CARD) at the n-terminus, which allows ARC to bind to the CARD and death domains on other 
proteins, and a proline/glutamate (PE) rich region at the c-terminus, which binds cytosolic 
calcium and p53 (56,57). These two domains allow ARC to act as an inhibitor of cell death by 
impeding the action of the factors involved in the apoptotic signalling pathways (56).  
The action of proteins vital to the intrinsic cell death pathway, including BAX, PUMA and 
BCL-2 associated death promoter (BAD), have been shown to be inhibited by ARC via the 
interaction of its CARD with the BH3 domains of PUMA and BAD and the c-terminus region of 
BAX (30,58). This inhibition prevents mitochondrial pore formation and the release of 
pro-apoptotic proteins. Further, PUMA plays an important role in the mitochondrial targeting of 
Drp-1 (19). With ARC bound to PUMA, Drp-1 is unable to translocate to the mitochondrial 
membrane and therefore is incapable of causing mitochondrial fission (19).  
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Furthermore, the ARC CARD domain can bind to the death domains located on the proteins 
involved in the DISC (30). This interaction can prevent DISC assembly, the activation of 
caspase-8, and therefore cell death through the extrinsic pathway (30). ARC can also bind directly 
to procaspase-8 through its death domain and inhibit its ability to be activated (55).  
The ability of ARC to bind calcium in the PE region can decrease the levels of cytosolic 
calcium during times of ER cell stress (59). Therefore, these calcium levels may not reach the 
required stress threshold to initiate the ER stress response (59). Additionally, ARC has been shown 
to have the ability to suppress CHOP production in response to ER stress in pancreatic beta cells. 
However, the mechanism behind this suppression is not clear (60).  
The DNA damage pathway can also be moderated by ARC through its ability to bind to the 
tetramerization domain of p53 via its PE region (61). This binding prevents p53 tetramerization 
and exposes a nuclear export signal, essentially inactivating p53 and exporting it from the nucleus, 
which eliminates its ability to act as a transcription factor for pro-apoptotic proteins (61). ARC 
additionally has the ability to bind to the death domain of caspase-2 through its CARD (55). 
Therefore, caspase-2 is unable to interact with PIDD and RAIDD to create the PIDDosome, 
ultimately preventing caspase-2 from being activated.  
Together, the ability of ARC to inhibit apoptosis through multiple pathways makes it a potent 
regulator of cell death. 
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2.2 Tissue expression 
Another unique aspect of ARC is its distinct tissue expression (56). ARC is highly expressed 
in terminally differentiated tissue such as cardiac muscle, neurons, and skeletal muscle, but is 
expressed at lower levels in most other tissues (55,62). In tissues where expression levels are high, 
its anti-apoptotic function plays an important role (63–65). In the heart, ARC has been shown to 
play a cardioprotective role (66). In patients with heart failure, ARC expression is decreased in 
cardiac tissue, making cardiomyocytes more susceptible to apoptosis (67). Furthermore, there is 
evidence to show that overexpression of ARC in rat cardiomyocytes reduced the extent of damage 
and prevented apoptosis after cardiac injury (68). Interestingly, our lab has shown that ARC 
expression is low in mouse C2C12 myocytes but increases significantly during differentiation. 
With this increased expression, these differentiated myocytes are highly resistant to 
apoptosis-inducing agents (69). Overall, ARC clearly plays an important role in preventing 
apoptosis in tissues where cell death can be detrimental to its function. Conversely, high levels of 
Figure 2: ARC has the ability to inhibit apoptosis through all the major cell death 
pathways. Adapted from Ludwig-Galezowska et al., 2011 (56). 
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ARC expression in cancerous tissue has been associated with chemoresistance and poor patient 
prognosis (19,70–72).  
2.3 Cellular localization  
ARC has been found to be expressed in the cytosol, nucleus, and on the mitochondrial 
membrane (62,70,72,73). Interestingly, the cellular localization of ARC appears to be highly 
variable depending on the tissue and malignancy status (62,72,73). In normal rat cardiomyocytes, 
rat hippocampal neurons, and human skeletal muscle, ARC is primarily located in the cytosol, 
whereas the localization appears to be more variable when tissue becomes malignant (62,72,73). 
In some cancer cell lines, including HT116 human colon cancer cells, DU145 human prostate 
cancer cells, and HeLa human cervical cancer cells, ARC has been found predominantly in the 
nucleus (62). In MCF7 human breast cancer cells and OCI-AML3 human acute myeloid leukemia 
(AML) cells, ARC was shown to be equally present in both cytoplasmic and nuclear 
compartments (72,74). Similarly, in human colon cancer patient samples, ARC was found to be 
present in both the cytosol and nucleus (73). However, there appear to be differences in ARC 
localization depending on the cancer grade (73). In moderately differentiated human colon cancer 
samples, ARC was found to be highly concentrated in the nucleus, in contrast to poorly and well 
differentiated samples where it was concentrated in the cytosol (73). It is clear from these findings 
that the primary location of ARC in a cell varies depending on the type of tissue.  
Furthermore, the cellular localization of ARC can change with phosphorylation (62,70). 
Casein kinase II (CK2) phosphorylates ARC at the T149 site and subsequently directs ARC to the 
mitochondrial membrane where is has been shown to bind to and inhibit caspase-8 (70). Whether 
phosphorylation of other amino acids residues on ARC are required for translocation to other 
cellular locations is yet to be determined (62).  
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2.4 Transcriptional regulation  
There are a variety of factors that impact the production and function of ARC. It is important 
to note that this research has been done in a variety of cell lines from different animals, making it 
difficult to make definitive conclusions about ARC regulation since the ARC gene sequence and 
transcription factors vary between rats, mice, and humans.  
At the transcriptional level, p53 has the ability to inhibit ARC transcription by binding to the 
promoter region on the rat ARC (NOL3) gene (58). Conversely, Ras is able to activate the human 
ARC promoter region through the mitogen-activated protein kinase/extracellular signal-regulated 
kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway (75). While specific 
transcription factors involved in ARC transcription have yet to be discovered, binding sites for 
transcription factors of the ETS family are present on the ARC promoter region (75). The 
production of ETS transcription factors has been shown to be activated by Ras/MEK/ERK 
signalling and the resulting transcription factors have been reported to be involved in 
carcinogenesis (75–77). Specifically, these transcription factors are involved in the promotion of 
genes that play a role in the malignant transformation of cells, including growth factor, cell cycle, 
and apoptotic genes (76). Additionally, this family of transcription factors has been associated with 
the progression of cancer through the promotion of genes related to invasion and metastasis (76). 
Ras signalling through the MEK/ERK and the PI3K pathways is also important to ARC 
transcription and protein levels in OCI3-AML human AML cells (74). Furthermore, the activation 
of the NIK/MAP3K14 non-canonical NFkB signalling pathway results in an increase in ARC 
protein levels in human AML cells (78). Interestingly, deregulation of this pathway is associated 
with lymphoid malignancies (79). Moreover, hypoxia inducing factor 1-alpha (HIF-1a) binds to 
the hypoxia response element 2 (HRE2) located on the human ARC promoter region and results 
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in increases in ARC transcription with hypoxia (80). However, it is important to note that the 
mouse and rat ARC promoter regions do not contain this HRE2 site (80). While there are multiple 
factors that have been shown to influence the transcriptional regulation of ARC, there are still 
many unanswered questions.  
 
3 Apoptosis and Cancer 
The balance between cell proliferation and cell death is critical in maintaining healthy 
tissue (2). Disease states arise when this balance is disrupted (2). Typically, neurological and 
cardiovascular diseases, such as Alzheimer’s and heart failure, are a result of excess apoptosis and 
subsequent loss of neurons and cardiac muscle (81,82). Conversely, inadequate apoptosis can lead 
to the accumulation of abnormal cells and the formation of a cancerous tumour (83). In reviews 
by Hanahan and Weinberg, the dysregulation of apoptosis was characterized as one of the 
hallmarks of cancer development (84,85).  
Cancer is simply defined as a disease that is the result of uncontrolled cell division and the 
accumulation of mutated or damaged cells (84,85). The development of cancer occurs in multiple 
steps and is often the result of several mutations that work together to create a malignant cell (84). 
There are numerous mutations that may occur in a cell that can result in the dysregulation of 
important cellular functions (84,85). The mutation powerful oncogenes, such as H-ras and c-myc, 
transform healthy cells into malignant cells and result in uncontrolled proliferation and 
growth (86). Normally, the mutations that occur would cause a cell to die, however, in order to 
allow these mutated cells to proliferate, apoptotic mechanisms are generally affected (83). The 
mutation of p53 in many cancer types results in the elimination of the DNA damage response, 
which also supports the accumulation of damaged cells (83,85). Additionally, it has been shown 
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that anti-apoptotic proteins are highly upregulated in some forms of cancer (83,85). The 
upregulation of ARC has been reported in cancer cell lines and cancer tissue samples (72,73,87). 
Specifically, human breast cancer and human colon cancer tissue show an upregulation of ARC 
compared to benign human breast and colon tissue (72,73). Similarly, ARC protein levels are 
increased in MCF7 human breast cancer cells compared to MCF10A benign breast cells (75). 
Additionally, ARC protein levels are increased in grade II and grade IV human brain cancer tissue 
compared to normal brain tissue (87).  ARC is also expressed in other cancer cell lines, including 
HeLa human cervical cancer cells and DU145 human prostate cancer cells (62). 
3.1 ARC and cancer  
While ARC is normally expressed at low levels in the majority of tissues, ARC becomes 
highly upregulated when a tissue becomes cancerous (71–73). This increase in ARC has been 
associated with resistance to chemotherapy and a poor prognosis (70–72).  
In a study by Carter and colleagues, blood and bone marrow samples from AML patients 
with high ARC protein levels were associated with a poor patient prognosis and a higher likelihood 
of relapse compared to samples that contained low ARC protein levels (71).  Additionally, the 
study found that ARC protein levels were higher at relapse than the levels at the time of the original 
diagnosis (71). Together, these results indicate that the prognosis of AML is partially associated 
with ARC protein levels.  
In numerous studies, high ARC protein levels have been shown to be a contributor to 
chemoresistance. Evidently, when ARC is knocked down in the human AML cell line OCI-AML3, 
these cells become more sensitive to the chemotherapeutic drug cytosine arabinoside (Ara-C), 
suggesting that ARC is inhibiting the apoptotic potential of the drug (74). A similar effect was 
found in HeLa cells, where ARC knockdown increased sensitivity to the chemotherapeutic drug 
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doxorubicin (DOX) (19). One mechanism by which DOX can induce apoptosis is through the 
activation of PUMA and subsequent mitochondrial fission (19). ARC is able to bind to PUMA and 
prevent mitochondrial fission, ultimately preventing DOX-induced cell death in HeLa cells (19). 
Therefore, the knockdown of ARC may have allowed for this mechanism of action to resume 
function. Furthermore, siRNA mediated ARC knockdown in U251MG glioblastoma cells 
increased their sensitivity to the chemotherapeutic drug VM-26 (teniposide) (87). Similarly, 
Hs578T breast cancer cells (which have a low ARC protein content) treated with DOX had a higher 
percentage of apoptotic nuclei following treatment compared to Hs578T breast cancer cells that 
overexpress ARC and were also treated with DOX (72). Overall, the results of these studies support 
the belief that ARC is responsible for chemoresistance in cancer.  
The p53 gene is mutated in the majority of cancers cases and this mutation has been shown 
to play a significant role in the progression of the disease (88). However, in cases where p53 
remains active, such as with MCF7 cells, it becomes highly localized to the cytosol, is no longer 
present in the nucleus, and therefore cannot play a role in transcription (89). This re-localization 
of p53 may be due to the binding of ARC to the p53 tetramerization domain and the exposure of 
a nuclear export signal (61). While it has been shown that the protein Parc may play a role in 
cytosolic retention of p53, Parc is expressed at very low levels in MCF7 breast cancer cells (61,90). 
On the other hand, ARC expression is very high in MCF7 cells, showing that ARC may be critical 
in the nuclear export of p53 in these cells (61). Interestingly, the nuclear localization of ARC has 
been associated with the presence wild-type p53 in breast cancer (61). Taken together, it is clear 
that ARC plays an important role in preventing wild-type p53 from acting as a transcription factor 
to induce apoptosis in cancer.  
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3.2 Apoptotic-related therapies  
Some chemotherapeutic drugs available today are focused on creating cellular stress within 
the cancer cell and subsequently causing cell death (91). However, if anti-apoptotic proteins, such 
as ARC, are highly expressed in the cancer cells or other components of apoptotic signalling are 
altered, the drug is likely to be ineffective (92). Therefore, the dysregulation of apoptosis and its 
related proteins in malignant cells present obvious targets for cancer treatment (91,92). 
DOX is a common chemotherapeutic drug that can cause DNA damage and generate free 
radicals to induce cell death in cancer cells (93). Normally, these conditions created by DOX would 
activate apoptotic pathways and ultimately result in cell death, however, many cancers are resistant 
to DOX (19,70). One possible reason for this resistance may be an increase in anti-apoptotic 
proteins, including ARC (19,70). It has been shown that DOX can decrease ARC protein levels 
and kill malignant cells, but the high dosage can damage other tissues (19,94).   
Researchers are beginning to investigate the effectiveness of combination therapy in the 
treatment of cancer (95). Since the increase in anti-apoptotic proteins appears to play a significant 
role in chemoresistance, inhibiting the actions of these proteins would clearly be beneficial to 
cancer therapy (92,95). Recently, a BCL-2 protein interaction inhibitor has been shown to be 
effective in causing apoptosis in clinical trials on its own (95). This type of drug can potentially 
be used in combination with other chemotherapeutic drugs to increase their effectiveness (95). 
More specifically, the use of a drug that can decrease anti-apoptotic proteins, such as ARC, in 
combination with apoptosis-inducing chemotherapeutic agents, such as DOX, may result in 
apoptosis of malignant cells (95).  
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4 Reporter Systems  
Reporter systems are commonly used in molecular biology to investigate the expression 
levels or localization of a particular protein of interest (96). The coding sequence of the particular 
protein is inserted into the reporter plasmid and when this plasmid is transfected into a cell, the 
protein is made with the addition of the reporter protein (97). Reporter systems are also commonly 
used for promoter analysis, in which the promoter region of interest is inserted into the reporter 
plasmid (98). In this case, when the promoter region is activated, the reporter protein is made 
independently and theoretically corresponds with the amount of gene expression (98). Luciferase 
and green fluorescent protein (GFP) are common reporter proteins that can be easily measured 
through luminescent and fluorescent assays (96).  
4.1 Green fluorescent protein 
GFP is a fluorescent protein originally derived from jellyfish (96,99). GFP fluoresces when 
exposed to the appropriate wavelength of light and does not require the addition of supplementary 
agents, allowing for the direct and simple detection of gene expression (96,99). GFP can also 
provide information regarding the location of a protein of interest in a cell if paired with fluorescent 
microscopy (99). Since GFP detection does not require the addition of cofactors, analysis can be 
done on living cells and the same cell set can be used for multiple readings (96,99). However, the 
auto-fluorescence of the cell presents a barrier to the detection of GFP fluorescence (99). With 
proteins that are not highly expressed or promoter regions that are not strongly activated, GFP 
fluorescence may not be bright enough to overcome the auto-fluorescence of the cell and the 
expression may not be detected (99). Additionally, the half-life of GFP is approximately 26 hours, 
which could result in fluorescence that is due to a build-up of GFP rather than the production of 
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the gene of interest (100). Overall, despite its potential drawbacks, GFP is a valuable tool for 
detecting gene expression due to its ease of detection and the ability for live cell analysis.  
4.2 Luciferase 
Firefly luciferase is an enzyme that catalyzes the reaction between luciferin, ATP, and 
oxygen to result in light production (Figure 4) (98). When the luciferase plasmid is activated, the 
luciferase enzyme is produced, leading to the build-up of luciferase within the cell (96). In order 
for the luciferase to be released from the cell and catalyze the reaction between luciferin, ATP, 
and oxygen, the cells must be lysed (96). This may limit the use of luciferase as a reporter, as it is 
not suitable for multiple readings on the same cell set. Furthermore, the addition of expensive 
substrates is required for the reaction to occur (101). However, luciferase is still a valuable tool for 
the detection of gene expression. Given that there is limited background noise due to the 
bioluminescent nature of the luciferase reaction, it is possible to detect small amounts of light 
production (100). Additionally, the fact that luciferase is an enzyme allows for the continuous 
reaction between luciferin, ATP, and oxygen and therefore amplification of the signal. Overall, the 
sensitivity of the luciferase assay makes luciferase an attractive reporter protein, however, the need 
for the cells to be lysed and the incorporation of additional substrates can limit its use. (102) 
 
 
 
 
 
	
	
	
	
	
Figure 3: The luciferase reaction. Adapted from Allard, 2008 (102) 
 
D-Luciferin + ATP + O2 Oxyluciferin + PPi + AMP + CO2 +      LIGHT 
Firefly luciferase + Mg
2+
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Rationale  
 Cancer is the leading cause of death in Canada (103). While the treatment options available 
are suitable for some cancers, chemoresistance is becoming a significant problem clinicians are 
faced with when developing treatment options (92,95).  
It has been shown that high ARC expression in some cancers contributes to the resistance 
to chemotherapeutic drugs due to the apoptotic repressive effects of ARC (70,72,73). In breast 
cancer, increased ARC levels have been shown to result in a decrease in sensitivity to 
chemotherapeutic drugs (72). In AML, high ARC protein levels have been shown to be associated 
with shorter remission durations and decreased overall survival (71). Knockdown of ARC in 
OCI-AML3 cells resulted in an increased sensitivity to the common AML chemotherapy drug 
Ara-C (71). Overall, ARC plays a role in chemoresistance in various cancers.  
 Many chemotherapeutic drugs function to create stress within a cell in order to induce cell 
death (91). However, if proteins involved in apoptotic pathways are mutated or upregulated, the 
effectiveness of these drugs can be attenuated (91,95). By discovering a pharmaceutical agent that 
has the ability to downregulate a powerful anti-apoptotic protein such as ARC, it is thought that 
apoptotic cell death through chemotherapeutic means will increase (95). Therefore, ARC presents 
a new therapeutic treatment target.    
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Purpose and Objectives 
 ARC is highly upregulated in cancerous tissue and has been associated with 
chemoresistance, making it an attractive and novel therapeutic target (70–72). The development 
of a reporter plasmid that contains the ARC promoter region would create a valuable tool to aid in 
the discovery of potential compounds that alter ARC expression, which could eventually have 
therapeutic use. Previous research that has analysed the ARC promoter region has used a 
luciferase-based reporter system (75,80). However, a GFP reporter system presents numerous 
advantageous over a luciferase reporter system for the use in a high throughput drug screen because 
GFP requires no additional substrates for detection and does not require the cells to be lysed before 
analysis (96,99). Therefore, the objective of this thesis project was to develop a novel GFP reporter 
plasmid to effectively monitor ARC expression.   
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Hypotheses  
It was hypothesized that:  
1. GFP fluorescence will correlate with ARC protein levels in MCF7 breast cancer cells. 
2. GFP fluorescence will increase with differentiation of C2C12 mouse myoblasts. This 
increase in GFP fluorescence will correlate with ARC protein levels.  
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Methods 
1 Plasmid development  
1.1 pGL3-0.75ARC-EGFP(luc-) and pGL3-0.75ModARC-EGFP(luc-) 
The pGL3-0.75ARC luciferase plasmid from Dr. Roger Foo (University of Singapore) was 
digested to remove the luciferase segment. pGL3-0.75ARC DNA was incubated with the HindIII 
and XbaI restriction enzymes (Thermo Scientific) and FastDigest green buffer (Thermo Scientific) 
at 37°C for 2 hours. Following digestion, the mixture was run through a 1% TAE agarose gel to 
separate the DNA based on size. Ethidium bromide (EtBr) was added to the gel for DNA 
visualization. The gel was visualised using an ultraviolet transilluminator (TL-2000 Ultraviolet 
Translinker, UVP) and the band that corresponded to pGL3-0.75ARC(luc-) was cut out. The DNA 
was subsequently isolated from the agarose gel and purified. First, the piece of agarose gel 
containing the pGL3-0.75ARC(luc-) DNA was incubated with a chaotropic agent and heated to 
dissolve the agarose gel. Next, the solution was added to a spin column and centrifuged, which 
separated the dissolved agarose gel and the DNA. The DNA bound to the membrane within the 
spin column. To remove impurities, wash buffer was added to the spin column and centrifuged. 
Finally, the DNA was removed from the membrane using an elution buffer and the pure DNA was 
collected at the bottom of the tube.  This resulted in the pGL3-0.75ARC(luc-) plasmid. The DNA 
concentration was measured using the NanoDrop 2000 (Thermo Scientific).  
The EGFP segment was taken from a pEGFP-N1 plasmid. The EGFP segment could not be 
directly removed from the pEGFP-N1 plasmid using the HindIII and XbaI restriction enzymes (to 
allow for insertion into the pGL3-0.75ARC(luc-) plasmid) due to the methylation of the XbaI 
restriction site. Consequently, polymerase chain reaction (PCR) was used to add a NheI site to the 
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end of the EGFP segment, since NheI and XbaI restrictions sites have compatible cohesive ends. 
The following protocol was used for the production of the EGFP segment:  
	
	
 
 
 
 
The PCR product was subsequently run through a 1% TAE agarose gel and the EGFP band 
was cut out. The DNA was subsequently isolated from the agarose gel and purified. First, the piece 
of agarose gel containing the PCR product DNA was incubated with a chaotropic agent and heated 
to dissolve the agarose gel. Next, the solution was added to a spin column and centrifuged, which 
separated the dissolved agarose gel and the DNA. The DNA bound to the membrane within the 
spin column. To remove impurities, wash buffer was added to the spin column and centrifuged. 
Finally, the DNA was removed from the membrane using an elution buffer and the pure DNA was 
collected at the bottom of the tube.  This resulted in the PCR-EGFP segment. The DNA 
concentration was measured using the NanoDrop 2000 (Thermo Scientific).  
Next, the PCR-EGFP segment was ligated into a pGEM plasmid. The pGEM plasmid and 
the PCR-EGFP segment were incubated with T4 ligase and T4 ligase buffer for 30 minutes at room 
temperature or overnight at 4°C. Following incubation, the ligation solution was added to 
competent cells (New England Biolabs) and placed on ice for 30 minutes. Next, the mixture was 
heat shocked at 42°C for 25 seconds, then immediately placed on ice for 2 minutes. Super optimal 
 EGFP from pEGFP-N1 plasmid 
Step 1 95°C, 3 min 
Step 2 95°C, 30 sec 
Step 3 58°C, 30 sec 
Step 4 72°C, 1 min 
Step 5 Repeat steps 2-4 for 28 cycles 
Step 6 72°C, 5 min 
 
Step 7 4°C forever 
Table 1: Thermal cycler (Bio-Rad Laboratories) 
protocol for the production of the EGFP segment. 
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broth with catabolite repression (SOC) was added to the transformation reaction and incubated at 
37°C for 90 minutes while shaking vigorously. Following incubation, 100 µL of the reaction was 
plated onto a lysogeny broth (LB) agar plate with ampicillin and incubated at 37°C overnight. The 
next day, the small colonies of bacteria that grew on the plate were picked using a pipette tip and 
placed into glass test tubes containing 5 mL of LB with ampicillin. The tubes were covered and 
incubated at 37°C overnight while shaking vigorously. The next day, the cloudy LB was purified. 
First, the cloudy LB was aliquoted into Eppendorf tubes, up to 5 mL in each tube. Next, the tubes 
were centrifuged to pellet the bacteria. Once the supernatant was removed, the bacteria was 
re-suspended in buffers that lysed the bacteria and precipitated the cell debris. The tubes were then 
centrifuged and the supernatant was added to a spin column. The DNA bound to the membrane 
within the spin column. To remove impurities, wash buffer was added to the spin column and 
centrifuged. Finally, the DNA was removed from the membrane using an elution buffer and the 
pure DNA was collected at the bottom of the tube. This resulted in the pGEM-EGFP plasmid. The 
DNA concentration was measured using the NanoDrop 2000 (Thermo Scientific).  
The pGEM-EGFP plasmid was digested to remove the EGFP segment. pGEM-EGFP DNA 
was incubated with the HindIII and NheI restriction enzymes (Thermo Scientific) and FastDigest 
green buffer (Thermo Scientific) at 37°C for 2 hours. Following digestion, the mixture was run 
through a 1% TAE agarose gel to separate the DNA based on size. EtBr was added to the gel for 
DNA visualization. The gel was visualised using an ultraviolet transilluminator (TL-2000 
Ultraviolet Translinker, UVP) and the band that corresponded to EGFP segment was cut out. The 
DNA was subsequently isolated from the agarose gel and purified. First, the piece of agarose gel 
containing the EGFP DNA was incubated with a chaotropic agent and heated to dissolve the 
agarose gel. Next, the solution was added to a spin column and centrifuged, which separated the 
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dissolved agarose gel and the DNA. The DNA bound to the membrane within the spin column. To 
remove impurities, wash buffer was added to the spin column and centrifuged. Finally, the DNA 
was removed from the membrane using an elution buffer and the pure DNA was collected at the 
bottom of the tube.  This resulted in the EGFP segment. The DNA concentration was measured 
using the NanoDrop 2000 (Thermo Scientific).  
The pGL3-0.75ARC(luc-) plasmid and the EGFP segment were incubated with T4 ligase 
and T4 ligase buffer for 30 minutes at room temperature or overnight at 4°C. Following incubation, 
the ligation solution was added to competent cells (New England Biolabs) and placed on ice for 
30 minutes. Next, the mixture was heat shocked at 42°C for 25 seconds, then immediately placed 
on ice for 2 minutes. SOC was added to the transformation reaction and incubated at 37°C for 90 
minutes while shaking vigorously. Following incubation, 100 µL of the reaction was plated onto 
a LB agar plate with ampicillin and incubated at 37°C overnight. The next day, the small colonies 
of bacteria that grew on the plate were picked using a pipette tip and placed into glass test tubes 
containing 5 mL of LB with ampicillin. The tubes were covered and incubated at 37°C overnight 
while shaking vigorously. The next day, the cloudy LB was purified. First, the cloudy LB was 
aliquoted into Eppendorf tubes, up to 5 mL in each tube. Next, the tubes were centrifuged to pellet 
the bacteria. Once the supernatant was removed, the bacteria was re-suspended in buffers that will 
lyse the bacteria and precipitate the cell debris. The tubes were then centrifuged and the supernatant 
was added to a spin column. The DNA bound to the membrane within the spin column. To remove 
impurities, wash buffer was added to the spin column and centrifuged. Finally, the DNA was 
removed from the membrane using an elution buffer and the pure DNA was collected at the bottom 
of the tube. This resulted in the pGL3-0.75ARC-EGFP(luc-) plasmid. The DNA concentration was 
measured using the NanoDrop 2000 (Thermo Scientific).	 
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Figure 4: pGL3-0.75ARC and pEGFP-N1 DNA digestion protocol. A) The 
pGL3-0.75ARC plasmid was digested with the HindIII and XbaI restriction 
enzymes and run through a 1% TAE agarose gel. The 3879 base pair band was 
cut out, and the DNA was isolated. This created the pGL3-0.75ARC(luc-) 
plasmid. B) Since the XbaI site located in the pEGFP-N1 plasmid is methylated, 
it cannot be cut using the required restriction enzymes. Therefore, a NheI site 
was added to the end of the EGFP segment using PCR. The PCR product  
(circles and triangles represent free nucleotides) was run through 1% TAE 
agarose gel; the 749 base pair band was cut out, and the DNA was isolated. The 
segment was then ligated into a pGEM plasmid. Next, the pGEM-EGFP 
plasmid was digested using the HindIII and NheI restriction enzymes and run 
through a 1% TAE agarose gel. The 749 base pair band was cut out, and the 
DNA was isolated. 
PCR- 
pGEM and PCR-EGFP Ligation 
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Compotent cells
DNA segmentOpen plasmid T4 ligase
T4 ligase 
buffer
Incubate 30 minutes at room 
temperature or overnight at 4ºC 
1 Incubate 30 minutes on ice
2 Heat shock for 2 minutes
3 Incubate on ice for 2 minutes
5 µL
950 µL 
SOC
100 µL
Incubate overnight at 37ºC 
If bacterial colonies form, the plasmid was 
successfully imported into the compotent cells  
Bacterial colonies were picked with a pipette tip 
and placed in a tube of LB
Shake in incubator at 37ºC overnight
Isolate DNA
Shake in incubator at 
37ºC for 90 minutes
pGL3-0.75ARC(luc-)
or
pEGFP-N1(CMV-)
EGFP
or
1005 ARC promoter
pGL3-0.75ARC-GFP(luc-)
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pGL3-1.005ARC-GFP(luc-)
or
pEGFP-N1-1.005ARC(CMV-)
EGFPpGL3-1.075ARC(luc-)
pGL3-0.75ARC-EGFP(luc-)
 pGL3-0.75AR (luc-) EGFP 
Figure 5: DNA ligation protocol. The pGL3-0.75ARC(luc-) 
plasmid and EGFP segment were ligated together to create the 
following final product: pGL3-0.75ARC-EGFP(luc-). 
	
26 
In order to remove a stop codon present in the pGL3-0.75ARC-EGFP(luc-) plasmid just 
before the EGFP sequence, this region of the plasmid was modified using the following primers: 
forward, 5’-TAC GCG TGC TAG CCC GGG CTC GAG-3’; reverse, 5’-AAG CTT CCG CTC 
CTG CGC GTT GCC CAT-3’. The forward primer contains the sequence for a XhoI restriction 
site and the beginning of the 750 base pair ARC promoter region and the reverse primer contains 
the sequence for the end for the 750 base pair ARC promoter region and a HindIII restriction site, 
creating a segment that does not contain the stop codon. The following thermal cycler protocol 
was used:  
 
 
 
 
 
The PCR product was subsequently run through a 1% TAE agarose gel, and the band 
corresponding with the modified ARC segment was cut out. The DNA was subsequently isolated 
from the agarose gel and purified. First, the piece of agarose gel containing the modified ARC 
segment DNA was incubated with a chaotropic agent and heated to dissolve the agarose gel. Next, 
the solution was added to a spin column and centrifuged, which separated the dissolved agarose 
gel and the DNA. The DNA bound to the membrane within the spin column. To remove impurities, 
wash buffer was added to the spin column and centrifuged. Finally, the DNA was removed from 
the membrane using an elution buffer and the pure DNA was collected at the bottom of the tube. 
 Modified ARC segment  
Step 1 94°C, 3 min 
Step 2 94°C, 1 min 
Step 3 60°C, 1 min 
Step 4 72°C, 1 min 
Step 5 Repeat steps 2-4 for 34 cycles 
Step 6 72°C, 10 min 
Step 7 4°C forever 
Table 2: Thermal cycler (Bio-Rad 
Laboratories) protocol for the production of 
the modified ARC segment. 
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This resulted in the PCR-modified ARC (PCR-ModARC) segment. The DNA concentration was 
measured using the NanoDrop 2000 (Thermo Scientific).  
Next, the PCR-ModARC segment was ligated into a pGEM plasmid. The pGEM plasmid 
and the PCR-ModARC segment were incubated with T4 ligase and T4 ligase buffer for 30 minutes 
at room temperature or overnight at 4°C. Following incubation, the ligation solution was added to 
competent cells (New England Biolabs) and placed on ice for 30 minutes. Next, the mixture was 
heat shocked at 42°C for 25 seconds, then immediately placed on ice for 2 minutes. SOC was 
added to the transformation reaction and incubated at 37°C for 90 minutes while shaking 
vigorously. Following incubation, 100 µL of the reaction was plated onto a LB agar plate with 
ampicillin and incubated at 37°C overnight. The next day, the small colonies of bacteria that grew 
on the plate were picked using a pipette tip and placed into glass test tubes containing 5 mL of LB 
with ampicillin. The tubes were covered and incubated at 37°C overnight while shaking 
vigorously. The next day, the cloudy LB was purified. First, the cloudy LB was aliquoted into 
Eppendorf tubes, up to 5 mL in each tube. Next, the tubes were centrifuged to pellet the bacteria. 
Once the supernatant was removed, the bacteria was re-suspended in buffers that lysed the bacteria 
and precipitated the cell debris. The tubes were then centrifuged and the supernatant was added to 
a spin column. The DNA bound to the membrane within the spin column. To remove impurities, 
wash buffer was added to the spin column and centrifuged. Finally, the DNA was removed from 
the membrane using an elution buffer and the pure DNA was collected at the bottom of the tube. 
This resulted in the pGEM-ModARC plasmid. The DNA concentration was measured using the 
NanoDrop 2000 (Thermo Scientific).  
The pGEM-ModARC plasmid was digested to remove the ModARC segment. 
pGEM-ModARC DNA was incubated with the XhoI and HindIII restriction enzymes (Thermo 
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Scientific) and FastDigest green buffer (Thermo Scientific) at 37°C for 2 hours. Following 
digestion, the mixture was run through a 1% TAE agarose gel to separate the DNA based on size. 
EtBr was added to the gel for DNA visualization. The gel was visualised using an ultraviolet 
transilluminator (TL-2000 Ultraviolet Translinker, UVP) and the band that corresponded to 
ModARC segment was cut out. The DNA was subsequently isolated from the agarose gel and 
purified. First, the piece of agarose gel containing the ModARC DNA was incubated with a 
chaotropic agent and heated to dissolve the agarose gel. Next, the solution was added to a spin 
column and centrifuged, which separated the dissolved agarose gel and the DNA. The DNA bound 
to the membrane within the spin column. To remove impurities, wash buffer was added to the spin 
column and centrifuged. Finally, the DNA was removed from the membrane using an elution 
buffer and the pure DNA was collected at the bottom of the tube.  This resulted in the ModARC 
segment. The DNA concentration was measured using the NanoDrop 2000 (Thermo Scientific).  
The pGL3-0.75ARC-EGFP(luc-) luciferase was digested to remove the segment containing 
the stop codon. pGL3-0.75ARC-EGFP(luc-) DNA was incubated with the XhoI and HindIII 
restriction enzymes (Thermo Scientific) and FastDigest green buffer (Thermo Scientific) at 37°C 
for 2 hours. Following digestion, the mixture was run through a 1% TAE agarose gel to separate 
the DNA based on size. EtBr was added to the gel for DNA visualization. The gel was visualised 
using an ultraviolet transilluminator (TL-2000 Ultraviolet Translinker, UVP) and the band that 
corresponded to pGL3-EGFP(luc-) was cut out. The DNA was subsequently isolated from the 
agarose gel and purified. First, the piece of agarose gel containing the pGL3-EGFP(luc-) DNA 
was incubated with a chaotropic agent and heated to dissolve the agarose gel. Next, the solution 
was added to a spin column and centrifuged, which separated the dissolved agarose gel and the 
DNA. The DNA bound to the membrane within the spin column. To remove impurities, wash 
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buffer was added to the spin column and centrifuged. Finally, the DNA was removed from the 
membrane using an elution buffer and the pure DNA was collected at the bottom of the tube. This 
resulted in the open pGL3-EGFP(luc-) plasmid. The DNA concentration was measured using the 
NanoDrop 2000 (Thermo Scientific).  
The open pGL3-EGFP(luc-) plasmid and ModARC segment were incubated with T4 ligase 
and T4 ligase buffer for 30 minutes at room temperature or overnight at 4°C. Following incubation, 
the ligation solution was added to competent cells (New England Biolabs) and placed on ice for 
30 minutes. Next, the mixture was heat shocked at 42°C for 25 seconds, then immediately placed 
on ice for 2 minutes. SOC was added to the transformation reaction and incubated at 37°C for 90 
minutes while shaking vigorously. Following incubation, 100 µL of the reaction was plated onto 
a LB agar plate with ampicillin and incubated at 37°C overnight. The next day, the small colonies 
of bacteria that grew on the plate were picked using a pipette tip and placed into glass test tubes 
containing 5 mL of LB with ampicillin. The tubes were covered and incubated at 37°C overnight 
while shaking vigorously. The next day, the cloudy LB was purified. First, the cloudy LB was 
aliquoted into Eppendorf tubes, up to 5 mL in each tube. Next, the tubes were centrifuged to pellet 
the bacteria. Once the supernatant was removed, the bacteria was re-suspended in buffers that will 
lyse the bacteria and precipitate the cell debris. The tubes were then centrifuged and the supernatant 
was added to a spin column. The DNA bound to the membrane within the spin column. To remove 
impurities, wash buffer was added to the spin column and centrifuged. Finally, the DNA was 
removed from the membrane using an elution buffer and the pure DNA was collected at the bottom 
of the tube. This resulted in the pGL3-0.75ModARC-EGFP(luc-) plasmid. The DNA concentration 
was measured using the NanoDrop 2000 (Thermo Scientific). 
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1.2 pGL3-1.005ARC-EGFP(luc-) 
The pGL3-1.005ARC luciferase plasmid from Dr. Olga Razorenova (University of 
California, Irvine) was digested to remove the luciferase segment. pGL3-1.005ARC DNA was 
incubated with the HindIII and XbaI restriction enzymes (Thermo Scientific) and FastDigest green 
buffer (Thermo Scientific) at 37°C for 2 hours. Following digestion, the mixture was run through 
a 1% TAE agarose gel to separate the DNA based on size. EtBr was added to the gel for DNA 
visualization. The gel was visualised using an ultraviolet transilluminator (TL-2000 Ultraviolet 
Translinker, UVP) and the band that corresponded to pGL3-1.005ARC(luc-) was cut out. The 
DNA was subsequently isolated from the agarose gel and purified. First, the piece of agarose gel 
containing the pGL3-1.005ARC(luc-) DNA was incubated with a chaotropic agent and heated to 
dissolve the agarose gel. Next, the solution was added to a spin column and centrifuged, which 
separated the dissolved agarose gel and the DNA. The DNA bound to the membrane within the 
spin column. To remove impurities, wash buffer was added to the spin column and centrifuged. 
Finally, the DNA was removed from the membrane using an elution buffer and the pure DNA was 
collected at the bottom of the tube. This resulted in the pGL3-1.005ARC(luc-) plasmid. The DNA 
concentration was measured using the NanoDrop 2000 (Thermo Scientific).  
The EGFP segment was taken from a pEGFP-N1 plasmid. The EGFP segment could not be 
directly removed from the pEGFP-N1 plasmid using the HindIII and XbaI restriction enzymes (to 
allow for insertion into the pGL3-1.005ARC(luc-) plasmid) due to the methylation of the XbaI 
restriction site. Consequently, polymerase chain reaction (PCR) was used to add a NheI site to the 
end of the EGFP segment, since NheI and XbaI restrictions sites have compatible cohesive ends. 
The following protocol was used for the production of the EGFP segment:  
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The PCR product was subsequently run through a 1% TAE agarose gel, and the EGFP band 
was cut out. The DNA was subsequently isolated from the agarose gel and purified. First, the piece 
of agarose gel containing the PCR product DNA was incubated with a chaotropic agent and heated 
to dissolve the agarose gel. Next, the solution was added to a spin column and centrifuged, which 
separated the dissolved agarose gel and the DNA. The DNA bound to the membrane within the 
spin column. To remove impurities, wash buffer was added to the spin column and centrifuged. 
Finally, the DNA was removed from the membrane using an elution buffer and the pure DNA was 
collected at the bottom of the tube.  This resulted in the PCR-EGFP segment. The DNA 
concentration was measured using the NanoDrop 2000 (Thermo Scientific).  
Next, the PCR-EGFP segment was ligated into a pGEM plasmid. The pGEM plasmid and 
the PCR-EGFP segment were incubated with T4 ligase and T4 ligase buffer for 30 minutes at room 
temperature or overnight at 4°C. Following incubation, the ligation solution was added to 
competent cells (New England Biolabs) and placed on ice for 30 minutes. Next, the mixture was 
heat shocked at 42°C for 25 seconds, then immediately placed on ice for 2 minutes. SOC was 
added to the transformation reaction and incubated at 37°C for 90 minutes while shaking 
vigorously. Following incubation, 100 µL of the reaction was plated onto a LB agar plate with 
 EGFP from pEGFP-N1 plasmid 
Step 1 95°C, 3 min 
Step 2 95°C, 30 sec 
Step 3 58°C, 30 sec 
Step 4 72°C, 1 min 
Step 5 Repeat steps 2-4 for 28 cycles 
Step 6 72°C, 5 min 
 
Step 7 4°C forever 
Table 3: Thermal cycler (Bio-Rad Laboratories) 
protocol for the production of the EGFP segment. 
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ampicillin and incubated at 37°C overnight. The next day, the small colonies of bacteria that grew 
on the plate were picked using a pipette tip and placed into glass test tubes containing 5 mL of LB 
with ampicillin. The tubes were covered and incubated at 37°C overnight while shaking 
vigorously. The next day, the cloudy LB was purified. First, the cloudy LB was aliquoted into 
Eppendorf tubes, up to 5 mL in each tube. Next, the tubes were centrifuged to pellet the bacteria. 
Once the supernatant was removed, the bacteria was re-suspended in buffers that lysed the bacteria 
and precipitated the cell debris. The tubes were then centrifuged and the supernatant was added to 
a spin column. The DNA bound to the membrane within the spin column. To remove impurities, 
wash buffer was added to the spin column and centrifuged. Finally, the DNA was removed from 
the membrane using an elution buffer and the pure DNA was collected at the bottom of the tube. 
This resulted in the pGEM-EGFP plasmid. The DNA concentration was measured using the 
NanoDrop 2000 (Thermo Scientific).  
The pGEM-EGFP plasmid was digested to remove the EGFP segment. pGEM-EGFP DNA 
was incubated with the HindIII and NheI restriction enzymes (Thermo Scientific) and FastDigest 
green buffer (Thermo Scientific) at 37°C for 2 hours. Following digestion, the mixture was run 
through a 1% TAE agarose gel to separate the DNA based on size. EtBr was added to the gel for 
DNA visualization. The gel was visualised using an ultraviolet transilluminator (TL-2000 
Ultraviolet Translinker, UVP) and the band that corresponded to EGFP segment was cut out. The 
DNA was subsequently isolated from the agarose gel and purified. First, the piece of agarose gel 
containing the EGFP DNA was incubated with a chaotropic agent and heated to dissolve the 
agarose gel. Next, the solution was added to a spin column and centrifuged, which separated the 
dissolved agarose gel and the DNA. The DNA bound to the membrane within the spin column. To 
remove impurities, wash buffer was added to the spin column and centrifuged. Finally, the DNA 
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was removed from the membrane using an elution buffer and the pure DNA was collected at the 
bottom of the tube.  This resulted in the EGFP segment. The DNA concentration was measured 
using the NanoDrop 2000 (Thermo Scientific).  
The pGL3-1.005ARC(luc-) plasmid and the EGFP segment were incubated with T4 ligase 
and T4 ligase buffer for 30 minutes at room temperature or overnight at 4°C. Following incubation, 
the ligation solution was added to competent cells (New England Biolabs) and placed on ice for 
30 minutes. Next, the mixture was heat shocked at 42°C for 25 seconds, then immediately placed 
on ice for 2 minutes. SOC was added to the transformation reaction and incubated at 37°C for 90 
minutes while shaking vigorously. Following incubation, 100 µL of the reaction was plated onto 
a LB agar plate with ampicillin and incubated at 37°C overnight. The next day, the small colonies 
of bacteria that grew on the plate were picked using a pipette tip and placed into glass test tubes 
containing 5 mL of LB with ampicillin. The tubes were covered and incubated at 37°C overnight 
while shaking vigorously. The next day, the cloudy LB was purified. First, the cloudy LB was 
aliquoted into Eppendorf tubes, up to 5 mL in each tube. Next, the tubes were centrifuged to pellet 
the bacteria. Once the supernatant was removed, the bacteria was re-suspended in buffers that will 
lyse the bacteria and precipitate the cell debris. The tubes were then centrifuged and the supernatant 
was added to a spin column. The DNA bound to the membrane within the spin column. To remove 
impurities, wash buffer was added to the spin column and centrifuged. Finally, the DNA was 
removed from the membrane using an elution buffer and the pure DNA was collected at the bottom 
of the tube. This resulted in the pGL3-1.005ARC-EGFP(luc-) plasmid. The DNA concentration 
was measured using the NanoDrop 2000 (Thermo Scientific). 
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Figure 6: pGL3-1.005ARC and pEGFP-N1 DNA digestion protocol. A) The 
pGL3-1.005ARC plasmid was digested with the HindIII and XbaI restriction 
enzymes and run through a 1% TAE agarose gel. The 4134 base pair band was 
cut out, and the DNA was isolated. This created the pGL3-1.005ARC(luc-) 
plasmid. B) Since the XbaI site located in the pEGFP-N1 plasmid is methylated, 
it cannot be cut using the required restriction enzymes. Therefore, a NheI site 
was added to the end of the EGFP segment and amplified using PCR. The PCR 
product was run through 1% TAE agarose gel; the 749 base pair band was cut 
out, and the DNA was isolated. The segment was then ligated into a pGEM 
plasmid. Next, the pGEM-EGFP plasmid was digested using the HindIII and 
NheI restriction enzymes and run through a 1% TAE agarose gel. The 749 base 
pair band was cut out, and the DNA was isolated. 
PCR- 
Ligation pGEM and PCR-EGFP 
 
41 4 bp 
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Incubate 30 minutes at room 
temperature or overnight at 4ºC 
1 Incubate 30 minutes on ice
2 Heat shock for 2 minutes
3 Incubate on ice for 2 minutes
5 µL
950 µL 
SOC
100 µL
Incubate overnight at 37ºC 
If bacterial colonies form, the plasmid was 
successfully imported into the compotent cells  
Bacterial colonies were picked with a pipette tip 
and placed in a tube of LB
Shake in incubator at 37ºC overnight
Isolate DNA
Shake in incubator at 
37ºC for 90 minutes
pGL3-0.75ARC(luc-)
or
pEGFP-N1(CMV-)
EGFP
or
1005 ARC promoter
pGL3-0.75ARC-GFP(luc-)
or
pGL3-1.005ARC-GFP(luc-)
or
pEGFP-N1-1.005ARC(CMV-)
EGFPpGL3-1.075ARC(luc-)
pGL3-0.75ARC-EGFP(luc-)
EGFP pGL3-1.005ARC(luc-) 
pGL3-1.005ARC-EGFP(luc-) 
Figure 7: DNA ligation protocol. The pGL3-1.005ARC(luc-) 
plasmid and EFGFP segment were ligated together to create the 
following final product: pGL3-1.005ARC-EGFP(luc-).  
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1.3 pEGFP-N1-1.005ARC(CMV-) 
To remove the CMV promoter from the pEGFP-N1 plasmid, AseI and BamHI restriction 
sites were used. Therefore, in order for the 1005 base pair ARC segment to be added to the 
EGFP-N1 plasmid, new restriction sites were required. The new restriction sites, AseI and BglII, 
were added to the beginning and end of the 1005 base pair ARC segment, respectively, using PCR. 
BglII was used because there is a BamHI site within the 1005 base pair ARC segment. BglII and 
BamHI have compatible cohesive ends. The following primers were used:  5’-TAA GCA ATT 
AAT AAG GGG CTT GGA ACC AGT CC-3’; reverse, 5’-TGC TTA AGA TCT GTG CGA CTG 
CAC GGA TTT TC-3’. The forward primer contains the sequence for a AseI restriction site and 
the beginning of the 1005 base pair ARC segment and the reverse primer contains the sequence 
for the end of the 1005 base pair ARC segment and a BglII restriction site.  The following thermal 
cycler protocol was used:  
 
 
 
 
 
 
The PCR product was digested using AseI and BglII restriction enzymes (Thermo 
Scientific/New England Biolabs) and FastDigest green buffer (Thermo Scientific) at 37°C for 2 
hours. Following digestion, the mixture was run through a 1% TAE agarose gel, and the band 
ARC segment from pGL3-
1.005ARC 
94°C, 2 min 
94°C, 30 sec 
60°C, 60 sec 
72°C, 2 min 
Repeat steps 2-4 for 34 cycles 
72°C, 5 min 
12°C forever 
Table 4: Thermal cycler (Bio-Rad Laboratories) 
protocol for the production of the 1005 base pair 
region of the ARC promoter with AseI and BglII 
restriction sites. 
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corresponding to the 1005 base pair ARC segment was cut out. The DNA was subsequently 
isolated from the agarose gel and purified. First, the piece of agarose gel containing the 1005 base 
pair ARC segment DNA was incubated with a chaotropic agent and heated to dissolve the agarose 
gel. Next, the solution was added to a spin column and centrifuged, which separated the dissolved 
agarose gel and the DNA. The DNA bound to the membrane within the spin column. To remove 
impurities, wash buffer was added to the spin column and centrifuged. Finally, the DNA was 
removed from the membrane using an elution buffer and the pure DNA was collected at the bottom 
of the tube. This resulted in the 1005 base pair ARC segment containing AseI and BglII restriction 
sites at the beginning and end of the segment, respectively. The DNA concentration was measured 
using the NanoDrop 2000 (Thermo Scientific).  
The pEGFP-N1 plasmid was digested to remove the CMV promoter. pEGFP-N1 DNA was 
incubated with the AseI and BamHI restriction enzymes (Thermo Scientific/New England Biolabs) 
and FastDigest green buffer (Thermo Scientific) at 37°C for 2 hours. Following digestion, the 
mixture was run through a 1% TAE agarose gel to separate the DNA based on size. The gel was 
visualised using an ultraviolet transilluminator (TL-2000 Ultraviolet Translinker, UVP) and the 
band that corresponded to the pEGFP-N1(CMV-) plasmid was cut out. The DNA was 
subsequently isolated from the agarose gel and purified. First, the piece of agarose gel containing 
the pEGFP-N1(CMV-) DNA was incubated with a chaotropic agent and heated to dissolve the 
agarose gel. Next, the solution was added to a spin column and centrifuged, which separated the 
dissolved agarose gel and the DNA. The DNA bound to the membrane within the spin column. To 
remove impurities, wash buffer was added to the spin column and centrifuged. Finally, the DNA 
was removed from the membrane using an elution buffer and the pure DNA was collected at the 
	
38 
bottom of the tube. This resulted in the pEGFP-N1(CMV-) plasmid. The DNA concentration was 
measured using the NanoDrop 2000 (Thermo Scientific).  
The pEGFP-N1(CMV-) plasmid and the 1005 base pair ARC segment were incubated with 
T4 ligase and T4 ligase buffer for 30 minutes at room temperature or overnight at 4°C. Following 
incubation, the ligation solution was added to competent cells (New England Biolabs) and placed 
on ice for 30 minutes. Next, the mixture was heat shocked at 42°C for 25 seconds, then 
immediately placed on ice for 2 minutes. SOC was added to the transformation reaction and 
incubated at 37°C for 90 minutes while shaking vigorously. Following incubation, 100 µL of the 
reaction was plated onto a LB agar plate with kanamycin and incubated at 37°C overnight. The 
next day, the small colonies of bacteria that grew on the plate were picked using a pipette tip and 
placed into glass test tubes containing 5 mL of LB with kanamycin. The tubes were covered and 
incubated at 37°C overnight while shaking vigorously. The next day, the cloudy LB was purified. 
First, the cloudy LB was aliquoted into Eppendorf tubes, up to 5 mL in each tube. Next, the tubes 
were centrifuged to pellet the bacteria. Once the supernatant was removed, the bacteria was 
re-suspended in buffers that will lyse the bacteria and precipitate the cell debris. The tubes were 
then centrifuged and the supernatant was added to a spin column. The DNA bound to the 
membrane within the spin column. To remove impurities, wash buffer was added to the spin 
column and centrifuged. Finally, the DNA was removed from the membrane using an elution 
buffer and the pure DNA was collected at the bottom of the tube. This resulted in the 
pEGFP-N1-1.005ARC(CMV-) plasmid. The DNA concentration was measured using the 
NanoDrop 2000 (Thermo Scientific).  
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Figure 5: pEGFP-N1 and pGL3-1.005ARC DNA digestion protocol. A) The CMV promoter was removed from the
pEGFP-N1 plasmid to allow the ARC promoter to drive production of EGFP. The pEGFP-N1 plasmid was digested using the
AseI and BamHI restriction enzymes and run through a 1% TAE agarose gel. The desired band was cut out, and the DNA
was isolated. This created the pEGFP(CMV-) plasmid. B) In order to insert the 1005 base pair ARC promoter segment into
the pEGFP-N1(CMV-) plasmid, new restriction sites were added to the beginning and end of the segment using PCR. The
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Figure 8: pEGFP-N1 and pGL3-1.005ARC DNA digestion protocol. A) The 
CMV promoter was removed from the pEGFP-N1 plasmid to allow the ARC 
promoter to drive production of EGFP. The pEGFP-N1 plasmid was digested 
using the AseI and BamHI restriction enzymes and run through a 1% TAE 
agarose gel. The 4097 bp band was cut out, and the DNA was isolated. This 
created the pEGFP(CMV-) plasmid. B) In order to insert the 1005 base pair 
ARC promoter segment into the pEGFP-N1(CMV-) plasmid, new restriction 
sites were added to the beginning and end of the segment using PCR. The PCR 
product was run through 1% TAE agarose gel; the 1005 bp band was cut out, 
and the DNA was isolated. The segment was then digested with AseI and BglII 
restriction enzymes and run through a 1% TAE agarose gel; the 1005 bp band 
was cut out. This created the 1005 base pair ARC promoter segment. 
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pEGFP-N1-1.005ARC(CMV-) Figure 9: DNA ligation protocol. The pEGFP-N1(CMV-) plasmid 
and 1005 bp ARC promoter segment were ligated together to create 
the following final product: pEGFP-N1-1.005ARC(CMV-).  
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1.4 Promoterless controls  
The promoterless, negative control plasmid was made by digesting the 
pGL3-0.75ARC-EGFP(luc-) plasmid using the Kpn-1 restriction enzyme, since there are Kpn-1 
restriction sites flanking the 750 base pair ARC promoter region. pGL3-0.75ARC-EGFP(luc-) 
DNA was incubated with the Kpn-1 restriction enzyme (Thermo Scientific) and FastDigest green 
buffer (Thermo Scientific) at 37°C for 2 hours. Following digestion, the mixture was run through 
a 1% TAE agarose gel to separate the DNA based on size. The gel was visualised using an 
ultraviolet transilluminator (TL-2000 Ultraviolet Translinker, UVP) and the band that 
corresponded to the pGL3-EGFP(luc-) plasmid was cut out. The DNA was subsequently isolated 
from the agarose gel and purified. First, the piece of agarose gel containing the pGL3-EGFP(luc-) 
DNA was incubated with a chaotropic agent and heated to dissolve the agarose gel. Next, the 
solution was added to a spin column and centrifuged, which separated the dissolved agarose gel 
and the DNA. The DNA bound to the membrane within the spin column. To remove impurities, 
wash buffer was added to the spin column and centrifuged. Finally, the DNA was removed from 
the membrane using an elution buffer and the pure DNA was collected at the bottom of the tube. 
This resulted in the open pGL3-EGFP(luc-) plasmid. The DNA concentration was measured using 
the NanoDrop 2000 (Thermo Scientific).  
Following digestion, the open ends of the plasmid were ligated back together. The 
pGL3-EGFP(luc-) plasmid was incubated with T4 ligase and T4 ligase buffer for 30 minutes at 
room temperature or overnight at 4°C. Following incubation, the ligation solution was added to 
competent cells (New England Biolabs) and placed on ice for 30 minutes. Next, the mixture was 
heat shocked at 42°C for 25 seconds, then immediately placed on ice for 2 minutes. SOC was 
added to the transformation reaction and incubated at 37°C for 90 minutes while shaking 
	
42 
vigorously. Following incubation, 100 µL of the reaction was plated onto a LB agar plate with 
ampicillin and incubated at 37°C overnight. The next day, the small colonies of bacteria that grew 
on the plate were picked using a pipette tip and placed into glass test tubes containing 5 mL of LB 
with ampicillin. The tubes were covered and incubated at 37°C overnight while shaking 
vigorously. The next day, the cloudy LB was purified. First, the cloudy LB was aliquoted into 
Eppendorf tubes, up to 5 mL in each tube. Next, the tubes were centrifuged to pellet the bacteria. 
Once the supernatant was removed, the bacteria was re-suspended in buffers that will lyse the 
bacteria and precipitate the cell debris. The tubes were then centrifuged and the supernatant was 
added to a spin column. The DNA bound to the membrane within the spin column. To remove 
impurities, wash buffer was added to the spin column and centrifuged. Finally, the DNA was 
removed from the membrane using an elution buffer and the pure DNA was collected at the bottom 
of the tube. This resulted in the pGL3-EGFP(luc-) plasmid. The DNA concentration was measured 
using the NanoDrop 2000 (Thermo Scientific). 
To make the promoterless, negative control plasmid for the luciferase assay, the 
pGL3-0.75ARC plasmid was digested with the Kpn-1 restriction enzyme, since there are Kpn-1 
restriction sites flanking the 750 base pair ARC promoter region. pGL3-0.75ARC DNA was 
incubated with the Kpn-1 restriction enzyme (Thermo Scientific) and FastDigest green buffer 
(Thermo Scientific) at 37°C for 2 hours. Following digestion, the mixture was run through a 1% 
TAE agarose gel to separate the DNA based on size. The gel was visualised using an ultraviolet 
transilluminator (TL-2000 Ultraviolet Translinker, UVP) and the band that corresponded to the 
pGL3 plasmid was cut out. The DNA was subsequently isolated from the agarose gel and purified. 
First, the piece of agarose gel containing the pGL3 DNA was incubated with a chaotropic agent 
and heated to dissolve the agarose gel. Next, the solution was added to a spin column and 
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centrifuged, which separated the dissolved agarose gel and the DNA. The DNA bound to the 
membrane within the spin column. To remove impurities, wash buffer was added to the spin 
column and centrifuged. Finally, the DNA was removed from the membrane using an elution 
buffer and the pure DNA was collected at the bottom of the tube. This resulted in the open pGL3 
plasmid. The DNA concentration was measured using the NanoDrop 2000 (Thermo Scientific).  
Following digestion, the open ends of the plasmid were ligated back together. The pGL3 
plasmid was incubated with T4 ligase and T4 ligase buffer for 30 minutes at room temperature or 
overnight at 4°C. Following incubation, the ligation solution was added to competent cells (New 
England Biolabs) and placed on ice for 30 minutes. Next, the mixture was heat shocked at 42°C 
for 25 seconds, then immediately placed on ice for 2 minutes. SOC was added to the transformation 
reaction and incubated at 37°C for 90 minutes while shaking vigorously. Following incubation, 
100 µL of the reaction was plated onto a LB agar plate with ampicillin and incubated at 37°C 
overnight. The next day, the small colonies of bacteria that grew on the plate were picked using a 
pipette tip and placed into glass test tubes containing 5 mL of LB with ampicillin. The tubes were 
covered and incubated at 37°C overnight while shaking vigorously. The next day, the cloudy LB 
was purified. First, the cloudy LB was aliquoted into Eppendorf tubes, up to 5 mL in each tube. 
Next, the tubes were centrifuged to pellet the bacteria. Once the supernatant was removed, the 
bacteria was re-suspended in buffers that will lyse the bacteria and precipitate the cell debris. The 
tubes were then centrifuged and the supernatant was added to a spin column. The DNA bound to 
the membrane within the spin column. To remove impurities, wash buffer was added to the spin 
column and centrifuged. Finally, the DNA was removed from the membrane using an elution 
buffer and the pure DNA was collected at the bottom of the tube. This resulted in the pGL3 
plasmid. The DNA concentration was measured using the NanoDrop 2000 (Thermo Scientific). 
	
44 
Since there were no compatible restriction sites in the pEGFP-N1 plasmid, the promoterless, 
negative control plasmid (pEGFP-N1(CMV-)) was made using scramble oligonucleotides 
containing AseI and BglII restriction sites (forward, 5’-TAA TGC ACT ACC AGA GCT AAC 
TCA-3’; reverse, 5’-GAT CTG AGT TAG CTC TGG TAG TGC AT-3’). The following protocol 
was used to anneal the sequences:  
 
 
 
 
	
The scramble segment was subsequently ligated into the open pEGFP-N1(CMV-) plasmid. 
The open pEGFP-N1(CMV-) plasmid and oligonucleotide segment were incubated with T4 ligase 
and T4 ligase buffer for 30 minutes at room temperature or overnight at 4°C. Following incubation, 
the ligation solution was added to competent cells (New England Biolabs) and placed on ice for 
30 minutes. Next, the mixture was heat shocked at 42°C for 25 seconds, then immediately placed 
on ice for 2 minutes. SOC was added to the transformation reaction and incubated at 37°C for 90 
minutes while shaking vigorously. Following incubation, 100 µL of the reaction was plated onto 
a LB agar plate with kanamycin and incubated at 37°C overnight. The next day, the small colonies 
of bacteria that grew on the plate were picked using a pipette tip and placed into glass test tubes 
containing 5 mL of LB with kanamycin. The tubes were covered and incubated at 37°C overnight 
while shaking vigorously. The next day, the cloudy LB was purified. First, the cloudy LB was 
aliquoted into Eppendorf tubes, up to 5 mL in each tube. Next, the tubes were centrifuged to pellet 
 Scram DNA  
Step 1 37°C, 30 min 
Step 2 95°C, 5 min 
Step 3 25°C, 10 sec 
Step 4 Rate 0.1 
Step 5 25°C forever 
Table 5: Thermal cycler (Bio-Rad 
Laboratories) protocol for the production of 
the scramble oligonucleotide. 
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the bacteria. Once the supernatant was removed, the bacteria was re-suspended in buffers that will 
lyse the bacteria and precipitate the cell debris. The tubes were then centrifuged and the supernatant 
was added to a spin column. The DNA bound to the membrane within the spin column. To remove 
impurities, wash buffer was added to the spin column and centrifuged. Finally, the DNA was 
removed from the membrane using an elution buffer and the pure DNA was collected at the bottom 
of the tube. This resulted in the promoterless control plasmid pEGFP-N1(CMV-). The DNA 
concentration was measured using the NanoDrop 2000 (Thermo Scientific). 
	
2 Cell culture 
MCF7 human breast cancer cells (ATCC), C2C12 mouse skeletal myoblast cells (ATCC), 
and human embryonic kidney cells (HEK-293) were cultured in growth media consisting of 
low-glucose Dulbecco’s Modified Eagle’s Medium (DMEM; Hyclone) containing 10% fetal 
bovine serum (FBS; Hyclone) and 1% penicillin/streptomycin (Hyclone) on polystyrene cell 
culture dishes (BD Sciences/Sarstedt/Grenier Bio One). Cells were incubated at 37°C and 5% CO2 
and were maintained by washing with phosphate buffered saline (PBS) and replacing growth 
media every other day unless otherwise specified. C2C12 differentiation was induced the day after 
transfection by replacing growth media with differentiation media consisting of low-glucose 
DMEM containing 2% horse serum (Hyclone) and 1% penicillin/streptomycin.  
Human skeletal muscle myoblast cells (HSMM; Lonza) were cultured in Skeletal Muscle 
Growth Media- 2 (SKGM-2) with 10% fetal bovine serum (FBS), 1% L-glutamine, 0.1% human 
epidermal growth factor, 0.1% dexamethasone, and 0.1% Gentamicin/Amphotericin-B (SKGM-2 
Bullet Kit, Lonza, Rochester, NY). In order for HSMM cells to remain adhered to the culture dish 
during differentiation, culture dishes were treated with Cultrex for 1 hour prior to plating the cells. 
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Differentiation was induced by replacing SKGM-2 with differentiation media of low-glucose 
DMEM containing 2% horse serum (Hyclone) and 1% penicillin/streptomycin. 
 
3 Transfection 
Cells were transfected with the specified plasmids. Transfections were performed with 
Lipofectamine 2000 (Invitrogen), Lipofectamine 3000 (Invitrogen), or jetPrime 
(Polyplus-transfection) and optimised according to the manufacturer’s instructions unless 
otherwise specified. Cells were transfected at approximately 80% confluency and incubated with 
the transfection mixture for 4 to 6 hours unless otherwise specified. Following the appropriate 
incubation time, the mixture was replaced with growth media.  
  
4 Luciferase assay  
To quantify luciferase activity, a Synergy H1 Microplate Reader (BioTek) was used. The 
protocol was adapted from Siebring-van Olst et al., 2013 (104). Cells were plated in an opaque, 
white 96 well plate (Grenier Bio One) at a density of 20 000 cells per well and transfected the 
following day. 48 hours post-transfection, growth media was removed, and cells were washed 
three times with PBS. The final PBS wash was aspirated, and the dry plate was placed in the -80°C 
freezer for 10 minutes to lyse the cells. After 10 minutes, the plate was removed and allowed to 
return to room temperature. During this time, the appropriate volume of firefly luciferase assay 
reagent (FLAR; 20mM Tricine, 100µM EDTA, 1.07mM MgCO3, 2.67mM MgSO4, 17mM DTT, 
250µM ATP, 250µM D-luciferin) was made (104). FLAR was added to each well using a 
multi-channel pipette. The plate was immediately placed in the plate reader and read every 3 
minutes for 12 minutes. The results from the second (3 minute) reading were used for analysis. 
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The luciferase activity detected in the blank wells was subtracted from the rest of the data. Data 
was normalised to the luciferase activity of the promoterless control plasmid and expressed in 
relative light units (RLU).  
5 Green fluorescent protein quantification  
To quantify EGFP fluorescence, a Synergy H1 Microplate Reader (BioTek) was used. Cells 
were plated in an opaque, white 96 well plate (Grenier Bio One) at a density of 20 000 cells per 
well and transfected the following day. 48 hours post-transfection, cells were washed, and growth 
media was replaced with PBS prior to reading. The excitation and emission wavelengths of EGFP 
were set to 480 nm and 509 nm, respectively. Data was normalised to the fluorescence of the 
promoterless control plasmid and expressed as relative fluorescence units (RFU).  
 
6 Flow cytometry 
Cells were washed with warm PBS and harvested via trypsinization. Cells were centrifuged 
at 1000g for 5 minutes at 4°C, resuspended in PBS, and centrifuged again at 1000g for 5 minutes 
at 4°C. Cells were resuspended in 1 mL of PBS, counted using the Z2 Coulter Counter 
(Beckman-Coulter) and diluted to 1 million cells per 1 mL of PBS. GFP fluorescence was 
measured using flow cytometry (FACSCalibur, BD Biosciences).  
 
7 Isolation and preparation of cell lysates 
Cells in culture were washed with warm PBS and isolated via trypsinization. Collected cells 
were centrifuged at 1000g for 5 minutes at 4°C. The pellet was then re-suspended in PBS and 
centrifuged again at 1000g for 5 minutes at 4°C. To produce whole cell lysates, lysis buffer (20mM 
HEPES, 10mM NaCl, 1.5mM MgCl, 1mM DTT, 20% glycerol and 0.1% Triton X-100; pH 7.4) 
and protease inhibitors (Complete Cocktail; Roche) were added to the collected cells and 
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subsequently sonicated. The cell lysate protein content was determined using the BCA protein 
assay method.  
 
8 Immunoblotting 
Equal amounts of protein were loaded into 10-12% SDS-PAGE gels, separated by 
electrophoresis, and transferred onto PVDF membranes (Bio-Rad Laboratories). Membranes were 
blocked for 1 hour at room temperature with 5% milk-Tris-buffered saline Tween 20. Next, 
membranes were incubated either overnight at 4°C or for 1 hour at room temperature with primary 
antibodies against the following proteins: ARC (Santa Cruz Biotechnologies) and GFP (Santa Cruz 
Biotechnologies). Membranes were then washed with tris-buffered saline with Tween 20 (TBS-T) 
and incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies for 1 
hour at room temperature. Protein bands were visualised using enhanced chemiluminescence 
western blotting detection reagents (GE Healthcare) and the ChemiGenius 2 Bio-Imaging System 
(Syngene).  
 
9 Statistical analyses  
All results are presented as means ± standard error of the mean. Comparisons were analysed 
using one-way analyses of variance (ANOVA) with Tukey’s post-hoc comparisons, or unpaired 
T-tests where appropriate. P < 0.05 was considered statistically significant. Statistical analyses 
were performed using Microsoft Excel and GraphPad Prism 6.  
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Results 
1 Modification of the pGL3-0.75ARC-GFP(luc-) plasmid 
As C2C12 cells differentiate, ARC protein levels increase (Figure 8). Therefore, C2C12 cell 
differentiation was used to show the relationship between ARC protein levels and GFP protein 
levels in cells transfected with a GFP reporter plasmid containing part of the ARC promoter region. 
Theoretically, as transfected C2C12 cells differentiate and ARC protein levels increase, GFP 
fluorescence should also increase.  
 
A pGL3-basic plasmid containing 0.75 kB of the human ARC promoter region most 
proximal to the translational start site of the short transcript variants (pGL3-0.75ARC; Figure 9) 
created by Dr. Roger Foo (National University of Singapore) was modified to encode green 
fluorescent protein (GFP) by Darin Bloemberg. This resulted in a pGL3-0.75ARC-GFP(luc-) 
plasmid (hereinafter referred to as FOO-ARC-GFP). When the FOO-ARC-GFP plasmid was 
transfected into C2C12 cells, it was evident that as ARC protein levels increased, the GFP 
fluorescence decreased.  Further analysis of the sequencing showed that a stop codon was present 
and in-frame just before the EGFP sequence, resulting in the loss of GFP protein production when 
the ARC promoter region was activated. The following primers were used to modify this region 
of the plasmid: forward, 5’-TAC GCG TGC TAG CCC GGG CTC GAG-3’; reverse, 5’-AAG 
CTT CCG CTC CTG CGC GTT GCC CAT-3’. Following amplification, the modified sequence 
was ligated into the pGL3-GFP(luc-) plasmid. The resulting plasmid 
Figure	1
ARC	increases	with	differentiation
0        1        2        3         4        5
Day of differentiation
ARC
30 kDa
Figure 10: As C2C12 cells differentiate, ARC 
protein levels increase. Representative immunoblot 
of whole cell lysate protein levels of ARC.  
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((pGL3-0.75MODARC-GFP(luc-)) and the pGL3-GFP(luc-) promoterless control plasmid were 
verified by DNA sequencing (performed by The Centre for Applied Genomics, The Hospital for 
Sick Children) (Appendix Figure 1 and 2). 
 
2 Transfections with the pGL3-0.75MODARC(luc-) plasmid  
Similar to the previous experiment, C2C12 cells were transfected with the 
pGL3-0.75MODARC-GFP(luc-) plasmid (hereinafter referred to as FOO-ModARC-GFP) or a 
pGL3-GFP(luc-) promoterless control plasmid (hereinafter referred to as the promoterless control) 
using a ratio of 1 µg DNA to 3 µL of Lipofectamine2000 reagent and differentiation was induced 
the next day. 24 hours after differentiation was induced, limited GFP fluorescence was detected 
under the fluorescent microscope (Figure 10). The following day, there was no GFP fluorescence 
detectable under the fluorescent microscope. 
This outcome suggested that there were still some underlying issues with the design of the 
plasmid or the cell model used. Therefore, the next step was to use a different cell line that was of 
human origin and displayed basal ARC protein, as opposed to C2C12 cells that induce ARC 
protein as they differentiate. Consequently, high pass MCF7 cells (HP MCF7 cells) were used. 
While highly passaged cells typically do not retain the same qualities as low passage cells (105), 
Figure 11: The ARC 
promoter region included 
in the pGL3-0.75ARC 
plasmid is in relation to the 
transcriptional start site of 
the short transcript 
variants. Adapted from 
NCBI Gene Report (Gene ID 
8996).  
Short 
transcript 
variants
(confirmed)
Long 
transcript 
variants
(confirmed)
NM_001276312.1
NM_001276319.1
NM_001276307.1
NM_001276309.1
NM_003946.6
NM_001185057.2
NM_001276311.1
Transcriptional 
start site
- 750 base pairs
Nol3 
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HP MCF7 cells still contain a high ARC protein content (Figure 11) and are therefore a viable 
model to show the potential relationship between ARC protein levels and GFP protein levels. HP 
MCF7 cells were transfected with the FOO-ModARC-GFP plasmid and the promoterless control 
plasmid using a ratio of 2 µg DNA to 6 µL of Lipofectamine2000 reagent. 24 and 48 hours 
post-transfection, no GFP fluorescence was detected under the fluorescent microscope.  
To rule out that this result was not due to a poor transfection efficiency, a different 
transfection reagent and protocol was used.	  HP MCF7 cells were transfected with the 
FOO-ModARC-GFP plasmid and the promoterless control plasmid using a ratio of 1 µg DNA to 
2 µL of jetPrime reagent. 24 and 48 hours post-transfection, no GFP fluorescence was detected 
under the fluorescent microscope. To be certain there was not a problem with the transfection 
protocols, HP MCF7 cells were transfected with a pDsRed2-Mito plasmid, an XIAP-GFP plasmid 
Figure 13: While HP MCF7 cells are physiologically and 
morphologically different than LP MCF7 cells, ARC protein 
is still highly expressed. Representative immunoblot of whole 
cell lysate protein levels of ARC. A: C2C12 cell standard, B: HP 
MCF7 cells.	
 
Figure 12: C2C12 cells were transfected and differentiation was induced the following day. On Day 
1 of differentiation, limited GFP fluorescence was detected. A) C2C12 cells transfected with the 
pGL3-0.75MODARC-GFP(luc-) plasmid. B) C2C12 cells transfected with the pGL3-GFP(luc-) 
promoterless control. Bar represents 200 µm. 
 
A B
A B
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A        B
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and the FOO-ModARC-GFP plasmid using either the Lipofectamine2000 reagent or the jetPrime 
reagent at various DNA to reagent ratios. The following day, DsRed and GFP fluorescence was 
detected in the cells transfected with the pDsRed2-Mito and XIAP-GFP plasmids; however, no 
GFP fluorescence was detected in any cells transfected with the FOO-ModARC-GFP plasmid. 
These results showed that the transfection protocols were successful in transporting plasmid DNA 
into the cells.  
Since there was no problem with the transfection efficiency, HP MCF7 cells were once again 
transfected with the FOO-ModARC-GFP plasmid and the promoterless control plasmid using a 
ratio of 1 µg DNA to 2 µL of jetPrime reagent for a more thorough analysis of the fluorescence. 
The following day, no GFP fluorescence was detected using the fluorescent microscope. 48 hours 
post-transfection, live cells were collected, and GFP fluorescence was analysed using an end-point 
GFP fluorescence assay (Figure 12). Cells were added to the wells of a black 96 well plate (Grenier 
Bio One) at different concentrations in triplicate. GFP fluorescence was not higher in cells 
transfected with the FOO-ModARC-GFP plasmid compared to cells transfected with the 
promoterless control plasmid when less than 50 000 cells were added to each well. However, when 
50 000 cells were added to each well, GFP fluorescence was slightly higher in cells transfected 
with the FOO-ModARC-GFP plasmid compared to cells transfected with the promoterless control 
plasmid. This trend continued when 100 000 cells were added to each well. Based on this result, it 
is possible that the plate reader was not sensitive enough to detect changes in GFP fluorescence 
when there were less than 50 000 cells added to each well. Nevertheless, the differences detected 
when 50 000 and 100 000 cells were added to each well were very small. Therefore, these cells 
were also analysed using flow cytometry. In cells transfected with the FOO-ModARC-GFP 
plasmid, flow cytometry analysis revealed that only 3.64% of the cells in the sample were GFP 
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positive (Figure 13). The flow cytometry results, in combination with the plate reader analysis, 
made it clear that the plasmid was not producing a significant amount of GFP protein with ARC 
promoter activation.  
 
 
 
Figure 15: In HP MCF7 cells transfected 
with the FOO-ModARC-GFP plasmid, 
only 3.64% of cells were GFP positive. 
“ARC 750 GFP” represents cells transfected 
with the pGL3-0.75MODARC-GFP(luc-) 
plasmid and “Empty GFP” represents cells 
transfected with the promoterless control 
plasmid.  0
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Next, HP MCF7 cells were transfected with the FOO-ModARC-GFP plasmid and starved in 
an attempt to manipulate ARC protein levels. Starvation increases the transcription factor Foxo3 
in C2C12 cells (106). In a study by Lu and colleagues, it was found that the transcription factor 
Foxo3a bound to and activated the rat ARC promoter region, which resulted in an increase in ARC 
protein content (107). Therefore, cells were incubated overnight in Hank’s Balanced Salt Solution 
or DMEM free of FBS. Unfortunately, starvation did not result in detectable GFP fluorescence 
under the fluorescent microscope the following day. It is important to note that this may have been 
because starvation did not increase ARC protein levels in MCF7 cells, as there are physiological 
differences between rodent and human cell lines; however, it may also indicate that the 
FOO-ModARC-GFP plasmid was not responding to ARC promoter activation.   
To determine if the FOO-ModARC-GFP plasmid would respond to ARC induction, the 
skeletal muscle differentiation model was used again. Since the ARC promoter region in the 
FOO-ModARC-GFP plasmid is human, human skeletal muscle myoblasts (HSMM) were 
transfected with the FOO-ModARC-GFP plasmid and the promoterless control plasmid using a 
ratio of 1 µg DNA to 3 µL of Lipofectamine2000 reagent or 2 µg DNA to 6 µL of 
Lipofectamine2000 reagent. Previous work in the lab has shown that, similar to C2C12 cells, ARC 
expression in HSMM cells increases during differentiation. After incubation with the 
FOO-ModARC-GFP plasmid DNA and reagent, cells did not appear to be healthy. Cells were 
allowed to recover in growth media for two days, then differentiation was induced. No GFP 
fluorescence was detected under the fluorescent microscope throughout the differentiation period.  
HP MCF7 cells were once again transfected with the FOO-ModARC-GFP plasmid and the 
promoterless control plasmid using a ratio of 2 µg DNA to 6 µL of Lipofectamine2000 reagent 
with the intension of being collected for ARC and GFP immunoblot analysis. This time, these cells 
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were transfected at a lower confluency than on previous occasions (approximately 60%). 
Surprisingly, GFP fluorescence was detected under the fluorescent microscope the following day 
(Figure 14A). 48 hours post-transfection, GFP fluorescence could still be detected (Figure 14B). 
This experiment was repeated to confirm the results (Figure 14C and 14D). Interestingly, there 
was no difference in the protocol used in this experiment other than the confluency at which the 
cells were transfected.  
 
 
 
Given this promising result, C2C12 cells were transfected at a lower confluency with the 
FOO-ModARC-GFP plasmid and the promoterless control plasmid using a ratio of 2 µg DNA to 
6 µL of Lipofectamine2000 reagent. Given that the previous experiment established that the 
FOO-ModARC-GFP plasmid produced GFP in a cell line with basal levels of ARC protein, the 
Figure 16: GFP fluorescence was detected under the fluorescent microscope in 
transfected HP MCF7 cells. A) 24 hours post-transfection. B) 48 hours post-
transfection. The experiment was repeated to confirm the results. C) 24 hours post-
transfection. D) 48 hours post-transfection. Bar represents 100 µm. 
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purpose of this experiment was to determine whether GFP protein levels would increase alongside 
the increase in ARC protein levels that occurs with skeletal muscle differentiation. The following 
day, differentiation was induced. Cells were collected over the differentiation period and analysed 
via immunoblotting. ARC protein content increased as the cells differentiated and GFP protein 
was detected on Day 0 and Day 1, but not after Day 2 in cells transfected with the FOO-ModARC-
GFP plasmid (Figure 15). While this was an improvement on the previous C2C12 cell experiments, 
GFP protein levels did not follow the same trend as ARC protein levels in C2C12 differentiation. 
It is important to note that the C2C12 experiments may not be effective because there are 
differences in the ARC promoter region between mouse and human; however, human skeletal 
muscle myoblasts were not used at this time because of their inability to handle the transfection 
protocol in the previous experiment. 
Figure 17: While ARC protein content increased as C2C12 cells differentiated, GFP protein content 
did not follow the same trend. A) Quantification of ARC protein levels in C2C12 cells transfected with the 
FOO-ModARC-GFP plasmid. B) Quantification of ARC protein levels in C2C12 cells transfected with the 
promoterless control plasmid. C) Whole cell lysate immunoblot of ARC. D) Quantification of GFP protein 
levels in cells transfected with the FOO-ModARC-GFP plasmid. E) Whole cell lysate immunoblot of GFP. 
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Because the previous experiments were done on HP MCF7 cells, low pass MCF7 (LP 
MCF7) cells were cultured and transfected to determine if a similar ARC and GFP protein level 
relationship could be seen. LP MCF7 cells were transfected with the FOO-ModARC-GFP plasmid 
using a ratio of 1 µg DNA to 3 µL of Lipofectamine2000 reagent or 2 µg DNA to 6 µL of 
Lipofectamine2000 reagent. The following day, the cells were dead. New transfection protocols 
were found in an attempt to limit the number of dead cells in the next experiment. LP MCF7 cells 
were transfected with the FOO-ModARC-GFP plasmid using the Maartje Vogel MCF7 
Lipofectamine2000 transfection protocol (Appendix Figure 3) or a ratio of 1 µg DNA to 2 µL of 
jetPrime reagent. The following day, no GFP fluorescence was detected using the fluorescent 
microscope. All the cells were dead 48 hours post-transfection. Next, the Lipofectamine2000 
protocol from Life Technologies (Appendix Figure 4) was followed with no modifications and 
there was no GFP fluorescence detected 24 hours post-transfection. Cells were dead the following 
day. There was no explanation as to why the LP MCF7 cells were dying with transfection, thus 
other cells types were used. 
Experiments in the literature using the original pGL3-0.75ARC plasmid from Dr. Roger Foo 
used HEK-293 cells and therefore, the same cells were used in this experiment (75). HEK-293 
cells are known to express very low endogenous levels of ARC protein (61). However, it was 
discovered that ARC protein levels increased as the cells became more confluent. Thus, these cells 
were used as an alternative method to show the relationship between ARC protein levels and GFP 
protein production. HEK-293 cells were transfected with the FOO-ModARC-GFP plasmid using 
a ratio of 2 µg DNA to 6 µL of Lipofectamine2000 reagent and allowed to grow for six days. GFP 
fluorescence was not detected under the fluorescent microscope on day 1, but was detectable on 
day 2 and 3. After this time, GFP fluorescence began to decrease (Figure 16A). Cells were 
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collected each day and analysed via immunoblotting (Figure 16B-E). While there were no 
significant differences in ARC protein content across the days in culture, it is clear that ARC 
protein content increased the longer the cells were in culture. GFP protein content was detectable 
on day two, but progressively decreased until day four. After day four, no GFP protein was 
detected. GFP fluorescence detected under the fluorescent microscope appeared to follow a similar 
trend as that seen in the immunoblot. However, the GFP fluorescence and protein levels did not 
increase as ARC protein levels increased.  
Figure	13
HEK	microscope	images	(6	days)
DAY 1 DAY 2 DAY 3
DAY 5 DAY 6
Figure 18: ARC protein levels slightly increases as HEK-293 cells become more confluent. However, GFP protein 
levels did not follow the same trend as ARC protein levels in HEK-293 cells. A) GFP fluorescence was detected under 
the fluorescent microscope in transfected HEK-293 cells. However, it was expected for the fluorescence to increase as the 
cells became more confluent (NOTE: An image of GFP fluorescence detected on day 4 was not taken). Bar represents 100 
µm. B) Quantification of ARC protein levels. C) Whole cell lysate immunoblot of ARC. D) Quantification of GFP protein 
levels. E) Whole cell lysate immunoblot of GFP. (n=1, in duplicate). 
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Next, a new transfection reagent, Lipofectamine3000, was used in LP MCF7 cells. 
Lipofectamine3000 results in a 2-fold improvement in expression over Lipofectamine2000 in 
MCF7 cells when transfecting with plasmid DNA (108). Therefore, LP MCF7 cells were 
transfected with the FOO-ModARC-GFP plasmid using a ratio of 1 µg DNA to 6 µL of 
Lipofectamine3000 reagent with the addition of 3.75 µL of the P3000 reagent. The following day, 
limited GFP fluorescence was detected under the fluorescent microscope (Figure 17A). Next, LP 
MCF7 cells transfected using 3.75 µL of the P3000 reagent were cultured for four days, then 
collected and analysed via immunoblotting (Figure 17B-E). While ARC protein content was high 
across all four days, GFP protein content peaked on day two, then decreased. In this case, it was 
clear that the Lipofectamine3000 reagent did not improve the GFP protein levels over the other 
reagents used in the previous experiments.  
\	
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3 Luciferase assay 
In light of the results of the prior experiments, the original pGL3-0.75ARC plasmid without 
any modifications was analysed using a luciferase assay. A pGL3-basic plasmid containing 
1.005 kB of the human ARC gene (pGL3-1.005ARC) that was obtained from Dr. Olga Razorenova 
(University of California, Irvine) and a promoterless pGL3-basic control plasmid were also 
analysed. Each plasmid was transfected into LP MCF7 cells using a ratio of 1 µg DNA to 2 µL of 
jetPrime reagent, and luciferase activity was analysed 48 hours later. The amount of luciferase 
activity from the pGL3-0.75ARC plasmid was similar to that of the promoterless pGL3-basic 
control, while the pGL3-1.005ARC plasmid had significantly more activity than both the 
promoterless control and the pGL3-0.75ARC plasmid (p<0.05) (Figure 18). It was evident that the 
pGL3-0.75ARC plasmid was not producing the reporter protein in response to ARC promoter 
activation even in its original state.    
 
Figure	17
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Figure 20: Luciferase activity of the promoterless 
control plasmid, the pGL3-1.005ARC plasmid, and the 
pGL3-0.75ARC plasmid. The pGL3-0.75ARC plasmid 
had less luciferase activity than expected. * p < 0.05 
compared to the control, # p < 0.05 compared to 0.75ARC 
(n=3, in triplicate).  
(Previous page) Figure 19: GFP protein was not highly expressed in LP MCF7 cells transfected 
with the FOO-ModARC-GFP plasmid using Lipofectamine3000 with the addition of 3.75µL of 
P3000 reagent. A) Some GFP fluorescence was detected under the fluorescent microscope in transfected 
LP MCF7 cells. Bar represents 100 µm. B) Quantification of ARC protein levels. C) Whole cell lysate 
immunoblot of ARC. D) Quantification of GFP protein levels. E) Whole cell lysate immunoblot of GFP. 
(n=1, in duplicate) 
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4 Modification of the pGL3-1.005ARC plasmid  
Given the results of the luciferase assay, the pGL3-basic plasmid containing 1.005 kB of the 
human ARC gene was modified to encode EGFP. This 1.005 kB region contains 701 base pairs of 
the human ARC promoter most proximal to the transcriptional start site of the long transcript 
variant, the first exon, and part of the first intron (Figure 19). The coding sequence for luciferase 
was excised via a HindIII and XbaI digest. The same EGFP segment used in the modification of 
the pGL3-0.75ARC plasmid was ligated into the pGL3-1.005ARC(luc-) plasmid. The resulting 
plasmid (pGL3-1.005ARC-GFP(luc-)) was verified by DNA sequencing (performed by The 
Centre for Applied Genomics, The Hospital for Sick Children) (Appendix Figure 5).	 
 
5 Transfections with the pGL3-1.005ARC-GFP(luc-) plasmid 
As mentioned previously, ARC protein levels increased as HEK-293 cells became more 
confluent. Therefore, HEK-293 cells were transfected with the pGL3-1.005ARC-GFP(luc-) 
plasmid (hereinafter referred to as RAZ-ARC-GFP(luc-)) and a pDsRed2-Mito plasmid using a 
ratio of 1 µg DNA to 2 µL of jetPrime reagent. The transfection mixture was removed after 5 
hours. HEK-293 cells were plated at various concentrations that would result in the cells being at 
various confluencies at the time of transfection, and therefore have different levels of ARC protein. 
Figure 21: The ARC 
promoter region included in 
the pGL3-1.005ARC 
plasmid is in relation to the 
transcriptional start site of 
the long transcript variants. 
Adapted from NCBI Gene 
Report (Gene ID 8996). 
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transcript 
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The following day, DsRed fluorescence was detected in cells transfected with the pDsRed2-Mito 
plasmid, but no GFP fluorescence was detected under the fluorescent microscope in cells 
transfected with the RAZ-ARC-GFP(luc-) plasmid.  
Immunoblot analysis revealed that ARC protein was not as highly expressed in confluent 
HEK-293 cells in comparison to other cell types, including MCF7 cells (Figure 20). Therefore, it 
was possible that the amount of ARC expression in confluent HEK-293 cells may have been too 
low to result in a detectable amount of GFP fluorescence under the fluorescent microscope. 
Therefore, LP MCF7 cells, which contain the highest ARC protein content out of the cell lines 
tested, were transfected with the RAZ-ARC-GFP(luc-) plasmid using various DNA and reagent 
concentrations. However, the following day, no GFP fluorescence was detected in any cells under 
the fluorescent microscope.  
 
6 Modification of the pGL3-1.005ARC-GFP(luc-) plasmid 
Given the results of the previous experiments, the RAZ-ARC-GFP(luc-) plasmid was 
modified. Rather than replacing the luciferase segment in the pGL3-1.005ARC plasmid with the 
Figure 22: ARC protein levels in different cell lines. ARC protein content in HEK-
293 cells is much lower than in MCF7 and C2C12 cells. A) Quantification of ARC 
protein levels. B) Whole cell lysate immunoblot of ARC (n=1).  
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EGFP segment from the pEGFP-N1 plasmid, the 1.005 kB segment of the ARC gene was cut out 
of the original pGL3-1.005ARC plasmid and ligated into the pEGFP-N1 plasmid. The CMV 
promoter present in the pEGFP-N1 vector was removed via an AseI and BamHI digest. The 
following primers were used to add an AseI restriction site at the start and a BglII restriction site 
at the end of the 1.005 kB segment of the ARC gene in the original plasmid from Dr. Razorenova: 
forward, 5’-TAA GCA ATT AAT AAG GGG CTT GGA ACC AGT CC-3’; reverse, 5’-TGC 
TTA AGA TCT GTG CGA CTG CAC GGA TTT TC-3’. Following amplification, the 1.005 kB 
segment of the ARC gene was ligated into the pEGFP-N1(CMV-) plasmid. The resulting plasmid 
(pEGFP-N1-1.005ARC(CMV-)) was verified by DNA sequencing (performed by The Centre for 
Applied Genomics, The Hospital for Sick Children) (Appendix Figure 6). 
 
7 Transfections with the pEGFP-N1-1.005ARC(CMV-) plasmid 
First, LP MCF7 cells were transfected with the pEGFP-N1-1.005ARC(CMV-) plasmid 
(hereinafter referred to as RAZ-ARC-EGFP) and a pEGFP-N1 positive control plasmid using a 
ratio of 1 µg DNA to 2 µL of jetPrime reagent. 24 and 48 hours post-transfection, there was a 
limited amount of GFP fluorescence detected under the fluorescent microscope in cells transfected 
with the RAZ-ARC-EGFP plasmid, but GFP fluorescence was detected in cells transfected with 
the pEGFP-N1 positive control plasmid (Figure 21). Once again, it was clear that the transfection 
of the MCF7 cells was successful given that there was GFP fluorescence in the cells transfected 
with the pEGFP-N1 positive control plasmid. However, only a small amount of GFP was detected 
in cells transfected with the RAZ-ARC-EGFP plasmid, even though MCF7 cells have a high ARC 
protein content.  
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8 Inducing hypoxia inducing factor 1 alpha as a means of increasing ARC expression  
The human 1.005 kB segment of the human ARC gene used in the plasmid contains hypoxia 
response elements (HRE), which are binding sites for hypoxia inducing factor 1 alpha 
(HIF-1a) (80). When HIF-1a binds to the HRE2 site located in the ARC promoter region, ARC 
expression increases (80,109). Therefore, in an attempt to activate the ARC promoter and 
hopefully GFP protein production, HIF-1a expression was induced using cobalt chloride 
(CoCl2) (110). LP MCF7 cells were treated with 0 µM, 75 µM, 100 µM or 125 µM CoCl2 made 
up in growth media for 0, 12, 18, or 24 hours. It appeared that 125 µM CoCl2 increased ARC 
expression the most after a 24 hour incubation period compared to the untreated, 0 hour control 
cells (Figure 22).	 
 
Figure	18
MCF7	cell	transfection	with	pEGFP-N1-1.005ARC(CMV-)
Microscope	images,	June	1	2016
DAY 1 DAY 2
Figure 23: Limited GFP fluorescence was detected under the fluorescent microscope 24 
and 48 hours post-transfection in LP MCF7 cells transfected with the RAZ-ARC-EGFP 
plasmid. Bar represents 100 µm. 
Figure	18
MCF7	cell	transfection	with	pEGFP-N1-1.005ARC(CMV-)
Microscope	images,	June	1	2016
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 Next, LP MCF7 cells were transfected with the appropriate plasmids and treated with CoCl2. 
LP MCF7 cells were transfected with the RAZ-ARC-EGFP plasmid, the pEGFP-N1 positive 
control plasmid and the pEGFP-N1(CMV-) negative control plasmid using a ratio of 1 µg DNA 
to 2 µL of jetPrime reagent. The following day, no GFP fluorescence was detected under the 
fluorescent microscope in cells transfected with the pEGFP-N1-1.005ARC(CMV-) plasmid. 48 
hours post-transfection, cells were treated with 125 µM CoCl2 for 24 hours, but no GFP 
fluorescence was detected under the fluorescent microscope following the treatment period in cells 
transfected with the RAZ-ARC-EGFP plasmid.  
LP MCF7 cells were again transfected with the RAZ-ARC-EGFP plasmid, the pEGFP-N1 
positive control plasmid and the pEGFP-N1(CMV-) negative control plasmid using a ratio of 1 µg 
DNA to 2 µL of jetPrime reagent. 48 hours post-transfection, cells were treated with 125 µM CoCl2 
for 24 hours. After the 24 hour incubation period, plate reader analysis showed there was no 
Figure 24: ARC protein levels in LP MCF7 cells when incubated in various 
concentrations of cobalt chloride for 0, 12, 18, or 24 hours. A) Quantification of ARC 
protein levels. B) Whole cell lysate immunoblot of ARC (n=1).  
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significant difference in GFP fluorescence with CoCl2 treatment in cells transfected with the 
RAZ-ARC-EGFP plasmid (Figure 23).  
 
 
9 C2C12 cell transfection and differentiation	 
C2C12 cell differentiation was once again used as a means of increasing ARC expression in 
order determine if the RAZ-ARC-EGFP plasmid would respond to increasing ARC expression by 
progressively increasing GFP expression across the C2C12 cell differentiation period. C2C12 cells 
were transfected with the RAZ-ARC-EGFP plasmid, the pEGFP-N1 positive control plasmid and 
the pEGFP-N1(CMV-) negative control plasmid using a ratio of 1 µg DNA to 2 µL of jetPrime 
reagent. The following day, differentiation was induced. Surprisingly, GFP fluorescence was 
detectable under the fluorescent microscope in cells transfected with the RAZ-ARC-EGFP 
plasmid throughout the differentiation process (Figure 24A). Plate reader analysis showed that 
GFP fluorescence in cells transfected with RAZ-ARC-EGFP plasmid was significantly higher than 
in cells transfected with the pEGFP-N1(CMV-) negative control plasmid (p<0.05) (Figure 24B). 
However, there was not a significant difference in GFP fluorescence throughout differentiation in 
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Figure 25: There was no difference in 
GFP fluorescence between cells 
transfected with the pEGFP-N1(CMV-) 
promoterless control plasmid and the 
RAZ-ARC-EGFP plasmid when treated 
with CoCl2. “Control” represents cells that 
were not treated. Cells were treated with 125 
µM CoCl2 for 24 hours (n=1, in 
hextuplicate).  
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cells transfected with the RAZ-ARC-EGFP plasmid (Figure 24C). Interestingly, immunoblot 
analysis revealed a pronounced increase in GFP protein content as cells differentiated (Figure 25).  
 
Figure	27
Differentiated	C2C12	cells	(transfected)
Microscope	images
DAY 0 DAY 1
DAY 3 DAY 5
Figure 26: GFP fluorescence in differentiated C2C12 cells transfected with the RAZ-ARC-EFGP plasmid. A) GFP 
fluorescence was detected under the fluorescent microscope throughout C2C12 cell differentiation. Bar represents 
100 µm. B) GFP fluorescence of cells transfected with the promoterless control or the RAZ-ARC-EGFP plasmid across 
the differentiation period. The GFP fluorescence of cells transfected with the RAZ-ARC-EGFP plasmid was significantly 
higher than the GFP fluorescence in cells transfected with the promoterless control plasmid at all time points. C) GFP 
fluorescence of cells transfected with the RAZ-ARC-EGFP across the differentiation period. There was no difference in 
GFP fluorescence as C2C12 cells differentiated. * = p<0.05 compared to promoterless control. (n=6, in triplicate).	
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Figure 27: ARC protein levels increased as C2C12 cells differentiated. GFP protein levels increased in 
differentiating C2C12 cells transfected with the RAZ-ARC-EGFP plasmid. A) Quantification of ARC protein 
levels. B) Whole cell lysate immunoblot of ARC. C) Quantification of GFP protein levels in cells transfected with 
the pEGFP-N1-1.005ARC(CMV-) plasmid. D) Whole cell lysate immunoblot of GFP. “CMV” represents cells 
transfected with the pEGFP-N1 positive control plasmid. “–VE” represented cells transfected with the 
pEGFP-N1(CMV-) negative control plasmid. “ARC GFP” represents cells transfected with the RAZ-ARC-EGFP 
plasmid (n=1).  
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Discussion 
	
 GFP reporter systems are commonly used in research as an easy way to determine the 
expression levels of a protein of interest (96). The purpose of this thesis was to develop a GFP 
reporter system that would allow for the analysis of ARC promoter activation. ARC is a potent 
anti-apoptotic protein that is highly upregulated in many cancers and has been associated with the 
resistance of cancer cells to chemotherapeutic drugs (62,70,72,73). It has been shown that a 
decrease in ARC protein levels results in an increased sensitivity to apoptosis induced by 
chemotherapeutic drugs, making ARC an appealing therapeutic target (70,71). A GFP plasmid 
under the control of the ARC promoter would allow for the examination of ARC expression as 
cells are incubated in various drugs. Theoretically, an increase or decrease of GFP fluorescence 
should correlate with an increase or decrease in ARC expression, respectively. GFP presents an 
advantage over the commonly used luciferase reporter systems for promoter analysis because 
fluorescence can be measured without lysing the cells and without the addition of other substrates 
(96,99). This allows for frequent monitoring of GFP fluorescence. The goal of this thesis was to 
develop a GFP plasmid under the control of the ARC promoter and analyse how GFP fluorescence 
changed in response to changes in ARC promoter activation. To accomplish this, a region of the 
ARC promoter was inserted into a GFP reporter plasmid with the expectation that the amount of 
GFP fluorescence would correlate with the amount of ARC promoter activation. To test this 
hypothesis, various cell types were transfected with the GFP plasmid containing the ARC promoter 
region. Following transfection, measures of GFP fluorescence were performed via fluorescent 
microscopy and plate reader assays, as well as measures of ARC and GFP protein content through 
Western blots.  
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 Previous studies that have analysed the ARC promoter region have used luciferase based 
reporter systems (75,80). The luciferase based reporter system is useful for promoter analysis 
because there is limited background noise, since the light production from a luciferase assay is the 
result of an enzymatic reaction and does not require an additional light source for excitation (102). 
This makes the assay highly sensitive because it is able to detect small changes in light 
production (101). However, the luciferase assay requires the cells to be lysed before analysis (96). 
The original goal of this project was to monitor the GFP expression response to an increase or 
decrease in ARC promoter activation in the same set of cells at various time points during 
incubation in different compounds. Measuring the GFP fluorescence in the same set of cells is 
important because it decreases the possibility that the changes in GFP fluorescence, and therefore 
ARC expression, are due to differences in the phenotype of the cells in each plate. Additionally, 
the fact that the cells do not need to be lysed means that GFP fluorescence can be measured at 
multiple stages of incubation, which is important in determining the critical time point(s) when 
GFP fluorescence, and therefore ARC promoter activation, changes over the course of the 
treatment period. Additionally, the measurement of GFP fluorescence does not require the addition 
of substrates before analysis (98). This saves time, effort, and money. While the GFP approach 
provides a number of advantages for the examination of ARC promoter activation, it requires the 
ARC promoter to be highly activated to produce a sufficient amount of GFP to overcome the 
autofluorescence of the cell (99). Since fluorescent assays require an additional light source to 
excite the green fluorescent molecules, cellular components can also be excited and fluoresce in 
the green light spectrum, resulting in background fluorescence (99). A constitutive promoter is 
commonly included in GFP reporter plasmids to allow for the sufficient production of GFP to 
overcome background fluorescence (99). However, it was important for this project that the ARC 
	
71 
promoter be the driver of GFP expression. With that being said, the use of the GFP plasmid driven 
by the ARC promoter in further analyses, such as a high throughput drug screen, was limited by 
the small amount of GFP fluorescence detected by the plate reader in C2C12 and MCF7 cells 
transfected with the RAZ-ARC-EGFP plasmid. Because there was a limited amount of GFP, a 
significant difference in GFP fluorescence was not detected by the plate reader. In the future, the 
detection of differences in GFP fluorescence will be vital to determining whether or not a 
compound is able to increase or decrease ARC promoter activation. This small amount of GFP 
produced by the RAZ-ARC-EGFP plasmid could be explained by limited activation of the ARC 
promoter region. Since the GFP reporter plasmid is under the control of the ARC promoter, the 
amount of GFP being made would correspond to the amount of ARC promoter activation and 
would theoretically be similar to the amount of ARC protein made (however, it is important to 
note that not all mRNA is translated into protein). If ARC protein levels are low in comparison to 
the total protein content of the cell, then GFP expression will also be low and may not be detected 
by a plate reader. Instead, a more sensitive detection instrument may be needed. Therefore, a plate 
reader assay may not be sensitive enough to detect changes in GFP fluorescence over a period of 
time in this experiment. However, this is likely not the case as we used C2C12 and MCF7 cells, 
which have been shown to have a higher ARC protein content than most other cell lines. 
Additionally, in this thesis and in previous literature, experiments using the luciferase plasmid 
under the control of the ARC promoter resulted in luciferase activity, showing that the luciferase 
plasmids produce the luciferase enzyme in response to ARC promoter activation (Figure 18) 
(75,80). Therefore, it is clear that the ARC promoter region is being activated at a sufficient level 
to produce luciferase. Ultimately, further work is required to produce a reporter plasmid that 
responds to ARC promoter activation.  
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While the use of GFP for promoter analysis is not common, one study was able to detect 
GFP fluorescence using a pGL3-EGFP(luc-) plasmid for SV40 promoter analysis in human 
embryonic lung fibroblasts (HLF) (111). In this previous work, HLF cells were transfected with a 
pGL3-EGFP(luc-) plasmid driven by the SV40 promoter and a Thy-1.1 (a mouse cell surface 
antigen) reference plasmid tagged with allophycocyanin (APC) (111). The HLF cells were sorted 
based on the detection of APC and the cells with a signal intensity above 6 AU were considered 
successfully transfected (111). This population of cells was then analysed for GFP fluorescence 
using a flow cytometer (111). Initially sorting cells based on a reference plasmid allowed for 
greater detection of GFP fluorescence compared to the amount of GFP fluorescence in the entire 
population. HLF cells have a low transfection efficiency, therefore, the number of cells that contain 
the GFP expressing plasmid in the entire cell population is low and consequently, so is the amount 
of GFP fluorescence (111). Sorting the HLF cells based on the reference plasmid limited the HLF 
cells that were analysed to those that were successfully transfected and therefore a greater amount 
of GFP fluorescence could be detected (111). However, while a flow cytometer may allow for 
greater detection of GFP fluorescence, this method is not as quick and simple as the plate reader 
fluorescence assay. For flow cytometer analysis, cells would need to be isolated and prepared for 
every test of GFP fluorescence. This would take away the ability to monitor and analyse the same 
cells over a period of time. Separate cells would be needed for each time point, which would 
require additional time, materials, and resources. Further, flow cytometry analysis can only be 
done at certain time points, therefore a critical time point (where there is a change in ARC promoter 
activity) could be missed. Additionally, analysing the cells using a flow cytometer would limit the 
number of compounds that could be screened at one time. The plate reader assay would allow for 
the detection of GFP fluorescence in a 96 (or more) well plate, which would be beneficial when 
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screening numerous drugs for their effect on ARC promoter activation. Overall, GFP is 
advantageous for the detection of ARC promoter activation in combination with a high-throughput 
drug screen, but more research is needed to construct a plasmid that will produce a reporter protein 
in response to ARC promoter activation that can be detected by plate reader analysis.   
 Data from several studies suggests that GFP causes cell damage and induces apoptosis in 
a variety of cell types (112). This can ultimately affect the results of a study, especially those 
focused on apoptosis. One study revealed that the transduction of GFP led to the generation of 
ROS and therefore increased the sensitivity of neuroblastoma cells to chemotherapeutic drugs, 
including DOX (113). However, it is important to note that the lentivirus vector used in this 
previous work contained a constitutive promoter and therefore the GFP expression was likely 
high (113). In this thesis, it is unlikely that the amount of GFP that was produced by the 
FOO-ARC-GFP, FOO-ModARC-GFP, RAZ-ARC-GFP(luc-) and RAZ-ARC-EGFP plasmids 
was enough to induce toxicity or apoptosis, and account for the poor results observed. However, 
if a new GFP plasmid is developed that successfully responds to ARC promoter activation and 
produces a significant amount of GFP, the possibility that GFP can cause cellular damage would 
need to be taken into consideration. This would be especially true if the plasmid was used for a 
high-throughput drug screen. The purpose of the pharmaceutical agent that decreases ARC 
expression is to sensitize cancer cells to apoptosis-inducing chemotherapeutic drugs. If the cancer 
cells are already sensitive to chemotherapeutic drugs due to GFP, the ability of the agents to 
decrease ARC promoter activation may be enhanced during the drug screen. Since the ARC protein 
plays a role in apoptotic signalling, it is possible that ARC may be involved in the increased 
sensitivity of cells to chemotherapeutic drugs. Luckily, it is possible to test whether or not GFP is 
having an effect on the sensitivity of cells to the compounds included in a high throughput screen 
	
74 
by transfecting cells with a plasmid that contains the ARC promoter region without the GFP coding 
sequence. If the results are the same in both the cells transfected with the GFP containing plasmid 
and the plasmid without the GFP coding sequence, it would be clear that GFP is not a significant 
problem. Overall, even though GFP allows for a quick and easy detection of ARC promoter 
activation, its ability to potentially damage the cell would need to be taken into consideration if a 
GFP plasmid containg the ARC promtoer is used in a high throughput drug screen. 
The pGL3-0.75ARC plasmid used in this thesis was constructed by Dr. Roger Foo 
(University of Singapore) (75). This plasmid was originally used by Wu and colleagues to 
determine if Ras could activate the 750 base pair ARC promoter region (75). The pGL3-0.75ARC 
plasmid was transfected into HEK-293 cells (which have low ARC protein content) along with an 
N-Ras or H-Ras vector (75). To determine if Ras activated the ARC promoter region, luciferase 
activity was measured using a firefly/Renilla luciferase assay (75). The results revealed that the 
N-Ras and H-Ras vectors were able to activate the ARC promoter region (75). For this thesis, the 
pGL3-0.75ARC plasmid was modified to encode EGFP instead of luciferase for easier detection. 
It was subsequently transfected into C2C12 cells which resulted in a limited amount of GFP 
fluorescence throughout differentiation, even though ARC protein content increases as C2C12 
cells differentiate. As this was not the result that we were expecting, the original pGL3-0.75ARC 
plasmid was tested for its ability to respond to ARC promoter activation by transfecting the original 
plasmid into MCF7 cells and performing a luciferase assay. MCF7 cells have a high ARC protein 
content compared to other cancer cell lines and were therefore selected for use in this thesis 
(Figure 20). Interestingly, the amount of luciferase activity in the MCF7 cells transfected with the 
original pGL3-0.75ARC plasmid was lower than the luciferase activity seen in cells transfected 
with the promoterless pGL3 control plasmid (Figure 18). This is different than the results reported 
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by Wu and colleagues that found an increase in luciferase activity when HEK-293 cells were 
transfected with the pGL3-0.75ARC plasmid and an N-Ras or H-Ras vector (75). This shows that 
the 750 base pair ARC promoter region is activated by Ras. To confirm that this was a problem 
with the pGL3-0.75ARC plasmid and not the luciferase assay protocol, a pGL3-1.005ARC 
plasmid was obtained from Dr. Olga Razorenova and tested for its ability to respond to ARC 
promoter activation in MCF7 cells. Previous work by Dr. Olga Razorenova showed that the 1005 
base pair ARC promoter region can be activated by hypoxia and the induction of HIF-1a, since 
luciferase activity increased when TK10 human kidney adenocarcinoma cells were transfected 
with the pGL3-1.005ARC plasmid and exposed to hypoxic conditions (0.5% oxygen) (80).  MCF7 
cells transfected with the pGL3-1.005ARC plasmid showed a significant amount of luciferase 
activity in comparison to the pGL3-0.75ARC plasmid and the promoterless pGL3 control plasmid 
(Figure 13). This illustrates that the pGL3-0.75ARC plasmid was not responding to ARC promoter 
activation in MCF7 cells and therefore was not producing luciferase.  
Since Wu and colleagues showed that the Ras pathway can stimulate the 750 base pair 
ARC promoter region and produce luciferase in HEK-293 cells with the addition of N-Ras or 
H-Ras, it was interesting that the plasmid did not produce the same results in this thesis (75). The 
MCF7 cells that were used for the luciferase assay in the present thesis have very high ARC protein 
levels, thus should contain the transcription factors and signaling pathways to promote ARC 
expression and therefore luciferase activity. Further, this cell line contains high levels of N-Ras, 
an integral part of the pathway involved in the activation of the ARC promoter region (114). 
Therefore, we believed that the luciferase assay in this thesis would give similar results to the paper 
by Wu and colleagues (75). However, it is possible that different ARC transcript variants are 
present in HEK-293 cells and MCF7 cells. Unfortunately, these same cells have not previously 
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been transfected with ARC plasmids in the literature.  In the paper by Wu and colleagues, the 
pGL3-0.75ARC plasmid was only transfected into HEK-293 cells to analyse ARC promoter 
activation and luciferase activity by the Ras signalling pathway (75). In the same paper, MCF7 
cells are used for other analyses, however, MCF7 cells were not used for the luciferase assays (75). 
In the paper by Razorenova and colleagues, the pGL3-1.005ARC plasmid was transfected into 
293FT human embryonic kidney cells and TK10 renal cell carcinoma cells (80). ARC promoter 
activation and luciferase activity was analysed in the 293FT and TK10 cells after cells were 
exposed to hypoxic conditions (80). It was mentioned in the same paper that the ARC protein 
content in MCF7 cells increases when hypoxia is induced; however, MCF7 cells were not used for 
luciferase assays (80). Further, C2C12 cells are not used for ARC promoter analysis in the 
literature. Therefore, the literature does not provide a clear view on whether different transcript 
variants may be playing a role in the results of this thesis. Furthermore, the ARC promoter regions 
incorporated into the plasmids used in this thesis are from two different areas of the ARC gene. 
Analysis of the sequences showed that the transcriptional start site defined by Dr. Roger Foo 
(pGL3-0.75ARC) corresponded with the short ARC transcript variants and the transcriptional start 
site defined by Dr. Olga Razorenova (pGL3-1.005ARC) corresponded with the long ARC 
transcript variants outlined on the National Institute of Health (NIH) Gene Bank (Figure 9 and 19). 
However, since it is unknown which transcript variants are present in different tissues, it is possible 
that the different promoter regions and different transcript variants contributed to the success or 
failure of the plasmid to produce GFP in different cell types. If this is the case, the plasmid from 
Dr. Razorenova (pGL3-1.005ARC) may not result in GFP production when transfected into cells 
containing the short ARC transcript variant given that the ARC promoter region included in this 
plasmid starts before the transcriptional start site of the short transcript variants. Conversely, the 
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promoter region present in the plasmid from Dr. Roger Foo (pGL3-0.75ARC) is located after the 
transcriptional start site of the long transcript variant, and therefore this region may not play a large 
role in the activation of transcription or contain all the elements necessary for transcription. 
Ultimately, the different promoter regions and transcript variants could have played a role in the 
results of this thesis. Therefore, determining the transcript variant present in C2C12 and MCF7 
cells would allow us to choose the plasmid with the promoter region that correlates with the ARC 
variant in the cell. To do so, primers that correspond with the ARC transcript variants can be 
designed to be used with real-time polymerase chain reaction. This will result in the amplification 
of the DNA of the transcript variant that is present in the tissue and allow us to establish which 
promoter region should be included in the reporter plasmid.  
Throughout this thesis, cell lines from both mouse and human were used. The C2C12 
mouse myoblasts were used because C2C12 cell differentiation was a known way to easily induce 
ARC protein production over a period of time, thus allowing for the monitoring of GFP expression 
as ARC protein levels increased. However, the ARC promoters in the plasmids used in this thesis 
are based on the human ARC sequence. With that being said, mice are commonly used in research 
because there are many similarities to the human genome (115). The similarities generally lie in 
the protein-coding regions, while differences are fairly pronounced in non-coding regions (115). 
However, some important regulatory elements that are contained in the non-coding regions (such 
as transcription factor binding sites) may still be present in both the mouse and human gene (116). 
Additionally, there may be some situations where a transcription factor is able to bind to a sequence 
that is not exactly the same as the established binding site sequence (116). Overall, there may be 
differences between the non-coding regions of mice and humans, but the important regulatory 
elements may still remain.  
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There are some notable differences between the human and mouse ARC gene and 
promoter. First, the human ARC gene is found on chromosome 16, whereas the ARC gene is found 
on chromosome 8 in mice (56). Additionally, the human ARC protein is 208 amino acids with a 
molecular mass of 22.6 kD, whereas the mouse ARC protein is 220 amino acids with a molecular 
mass of 24.5 kD (56). Interestingly, Figure 11 shows that the ARC protein is larger in C2C12 
mouse myoblasts compared to the ARC protein in MCF7 human breast cancer cells. When the 
entire human ARC sequence was compared to the entire mouse ARC sequence using the NIH 
Basic Local Alignment Search Tool (BLAST), there were few similarities found in the promoter 
area. However, the RAZ-ARC-EGFP plasmid, which contains a segment of the human ARC 
promoter region, responded the best to increasing ARC expression during C2C12 mouse myoblast 
cell differentiation. The factor(s) responsible for the increase in ARC during C2C12 cell 
differentiation is not known, therefore, it is possible that this factor(s) may bind to a sequence site 
that is present within the 1005 base pair human ARC promoter region that is similar to the sequence 
that the transcription factor(s) binds to in the mouse ARC promoter region. This could be explained 
by the fact that some regulatory elements in the promoter regions of human and mouse genes are 
conserved, or that the transcription factor binding sequences do not need to completely align with 
the established transcription factor binding sites (116). Therefore, the human ARC promoter in the 
RAZ-ARC-EGFP plasmid may have been activated by the factor(s) responsible for C2C12 mouse 
myoblast differentiation to produce GFP.  
Overall, a GFP reporter plasmid is a valuable tool to use in combination with a high 
throughput drug screen because it allows the gene or promoter of interest to be analysed on 
numerous occasions over a period of time on the same set of cells. ARC is a potent anti-apoptotic 
protein that is highly upregulated in cancer cells and is an attractive therapeutic target because it 
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has been shown to contribute to the resistance of cancer cells to chemotherapeutic drugs 
(62,70,72,73). However, the results of this thesis show that more work is required to develop an 
effective reporter plasmid driven by the ARC promoter. Since the fluorescent reporter system 
presents many advantages over the luciferase reporter system, it may be beneficial to insert the 
ARC promoter region into a red fluorescent protein (RFP) plasmid. Autofluorescence of the cell 
typically occurs in the green light spectrum, therefore, some background noise may be removed 
by moving to an RFP plasmid (117). Additionally, given that there are different ARC transcript 
variants, it would be valuable to determine which variant is present in the cell types that will be 
used so the correct promoter region can be inserted into the plasmid. Ultimately, there is more 
research needed to develop an effective reporter plasmid to monitor ARC expression levels.  
 
Limitations 
	
 There were a variety of limitations that impacted the results of this thesis. First, the 
plasmids used in this thesis are manufactured pieces of circular DNA. While using reporter 
plasmids with portions of genes is a widely used method for gene expression and promoter 
analysis, it may not allow researchers to gain insight into what is actually occurring in the cell 
because the portion of the gene included in the plasmid is not in the context of the whole 
genome (118). Therefore, some vital components (such as transcription factor binding sites or 
enhancer sequences) may not be present (118). In terms of promoter analysis and reporter 
plasmids, the portion of the promoter region taken out of the context of the genome may not have 
the same effect on the promotion of transcription (118). It is possible that the regulation of the 
promoter region may also be altered when it is inserted into a plasmid (118). Therefore, the 
promoter region in the reporter plasmid may not respond to the activating elements in the same 
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way it would in the genome and ultimately would not produce the expected reporter protein (118). 
Additionally, it is possible that all the elements necessary for promoter activation are not present 
within the portion of the promoter region in the plasmids (118). It has been shown that there are 
other areas of the genome that are important for the activation of transcription other than the 
promoter region. Enhancer sequences, for example, bind proteins that are important to the 
interaction of the elements involved in transcription (119). Ultimately, the fact that the ARC 
promoter region was taken out of the context of the genome and inserted into a GFP reporter 
plasmid may have limited the amount of GFP that was produced due to a change in promoter 
regulation, and therefore limited the results of this thesis.  
 Transfection of the ARC plasmids into a variety of cell lines was a critical component of 
this thesis. In this thesis, cells were transfected using both cationic lipid and cationic polymer 
transfection methods. However, this method limited the cell lines that could be used. Because the 
primary human myoblasts died following transfection, C2C12 mouse myoblasts were used in this 
thesis. Additionally, some cell lines have a low transfection efficiency. Therefore, the packaged 
plasmid DNA could not easily enter the cell and be expressed. Even though the manufacturer’s 
transfection protocols for both Lipofectamine2000 and jetPrime were manipulated to include 
varying amounts of plasmid DNA and reagents, the transfection method was a problem throughout 
this thesis.   
 
Future directions 
	
 While this project may ultimately result in the discovery of a drug that can be used to 
decrease ARC protein levels in cancer cells, there are some aspects that should be considered 
before moving forward. First, a fluorescent reporter system was used for this project to allow for 
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the simple detection of a change in promoter activation. With this system, we hypothesized we 
would be able to incubate the cells in various drugs and simply run a plate reader assay to determine 
whether or not the fluorescence decreased. However, it is possible that a GFP reporter system may 
not be powerful enough for promoter analysis, especially with the ARC promoter. Further, the 
autofluorescence of the cell that occurs in the green light spectrum may be limiting the detected 
GFP fluorescence. In order to test whether there is a problem with the activation of the ARC 
promoter or the detection of GFP, the luciferase plasmids containing the ARC promoter and the 
GFP plasmids containing the ARC promoter can be tested in tandem. If there is a problem with 
the activation of the ARC promoter, both the luciferase assay and the GFP fluorescence assay 
should be affected. However, if there is a problem with the detection of GFP, only the GFP 
fluorescence assay should be affected. Additionally, it would be interesting to examine the amount 
of fluorescence detected by a plate reader when a RFP plasmid is driven by the ARC promoter. 
Additionally, it may be beneficial to explore other simple options, such as secreted alkaline 
phosphatase (SEAP). Similar to other reporter genes, a segment of DNA is inserted into a SEAP 
reporter plasmid. The activation of this segment of DNA results in the production of SEAP and 
this is secreted into the cell culture medium (98). SEAP can be detected using a chemiluminescent 
assay (96). This method is easy to use and would be appropriate for the analysis of promoter 
activation over a period of time as it does not require the cells to be lysed (96). The cell media is 
collected and analysed for the presence of SEAP (96). 
Second, it is possible that different transcript variants are present in different cell types. It 
would be beneficial to know which transcript variant is present in the cell in order to choose the 
appropriate promoter region to use in the reporter plasmid. While it is not possible to insert the 
entire genome into a reporter plasmid, using the correct transcript variant for the cell line may 
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result in a more successful experiment. Real-time polymerase chain reaction will allow us to 
determine which transcript variant is present in the cell lines examined.  
Another method to increase ARC levels would be to co-transfect cells with the transcription 
factors that are known to drive ARC transcription along with the reporter plasmid containing the 
ARC promoter region. This would provide us with an additional model to analyse ARC promoter 
activation and the response of the reporter plasmid.  
To further understand ARC transcription, ARC mRNA expression can be measured. This 
will provide us with information regarding the amount of ARC mRNA that is being made and help 
us better understand the levels of the reporter protein and its relationship with ARC transcription.  
 Finally, if a successful reporter plasmid is made, there are numerous applications. This 
plasmid can be used in various cell types to track the levels of ARC expression. Since ARC appears 
to play an important role in skeletal and cardiac muscle, the plasmid could be used to enhance our 
understanding of how different conditions, such as aging or disease, affect ARC levels. 
Additionally, this plasmid may be able to help researchers understand the transcriptional regulation 
of ARC and the transcription factors involved. With a successful reporter plasmid, we may be able 
to use this plasmid to find a drug that would decrease ARC expression and hopefully increase the 
sensitivity of cancer cells to apoptosis-inducing chemotherapeutic drugs. Transfected cells can be 
incubated with various drugs for a period of time and the ARC expression levels can be tracked 
using a plate reader assay. Additionally, there is a chance that a drug may increase ARC 
expression. This could have implications in diseases where too much apoptosis is occurring, such 
as Alzheimer’s and heart disease.  
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Appendix 
 
 
 
 
 
 
 
 
Appendix Figure 1: Sequencing results of pGL3-0.75MODARC-GFP(luc-) plasmid. 
Sequenced using the RV3P primer.  
ARC promoter region 
First 7 amino acids of ARC protein 
HindIII restriction site 
GFP 
 
gtcrrtmggtgcagamtttctctatcgataggtaccgagctcttacgcgtgctagcccgg 
gctcgagcggccgccagtgtgatggatatctgcagaattcgccctttgtaaaacgacggc 
cagttatcagggtcaaggtaaggggagaggggcagggaggctctcagcactttgtgctct 
gggttcagaggggactggaggatagagtatggaagcagggagctctgatcctgggttctg 
cagggccaaagcaggaggcagaaggctggacttagtaagtggtgaggatggtgagagaaa 
tattcagcagtcagactggaaaggacttgtctgcaagctgggtgtggagtatcagcatca 
atcctaggtttttctgcctggttaggtggggaagcagatttgagagaaagaccttagttt 
ggataaacggggtctgaactcgcctcggatttgccgggggtggagctcaggacgtcctgg 
ttggggagggcattcagagagtagatgccagtcctgggaaaggcaggggaggagaggaga 
gccacggctgacgcttggggacagaaggaggagcctgaggaggagacaggacagagcgtc 
tggagaggcaggaggacaccgagttccccgtgttggcctccaggtcctgtgcttgcggag 
ccgtccggcggctgggatcgaggtgaacttaaaccccagcctgggtgttcactgggggca 
ttgagggagtggtcagaggcggcgagggcagcggggagggcaaccccccattacttctct 
cccctttccccatgcagccccgacaatgggcaacgcgcacgagcggaagcttgccaccat 
ggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacgg 
cgacgtaaacggccacaagttcagcgtgtccgsgagggcgagggcgatgccacctacggc 
aagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgcctggaccacctcgt 
gaccaccctgacctacgsgtgcagtgctcagcgctacccgacacatgaagcagcacgact 
ctcagtcgcatgcccgagctacgtcaggagcgcacatctctcagacgacgcactacagac 
gsacgaggtgagtcgaggcgaccctgtgacgcatcgactkaggcatcgactcagagacgc 
actctggcaagctgatactwcaagtcwmaagtc 
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Appendix Figure 2: Sequencing results of the pGL3-GFP(luc-) promoterless control 
plasmid. Sequenced using the RV3P primer.  
pGL3-basic 
KpnI restriction site 
HindIII restriction site 
GFP 
 
 
gtcattmgtgcmkaamtttctctatcgataggtaccaagcttgccaccatggtgagcaag 
ggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaac 
ggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgacc 
ctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccacc 
ctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttc 
ttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgac 
ggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatc 
gagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtac 
aactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtg 
aacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccag 
cagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacc 
cagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttc 
gtgaccgccgccgggatcactctcggcatggacgagctgtacaagtaaagcggccgcgac 
gctagagtcggggcggccggccgcttcgagcagacatgataagatacattgatgagtttg 
gacaaaccacaactagaatgcagtgaaaaaaatgctttatttgtgaaatttgtgatgcta 
ttgctttatttgtaaccattataagctgcaataaacaagttaacaacaacaattgcattc 
attttatgtttcagtcaggarwgtttttgaaagttttttaaagcargtaaaacctctaca 
atgtggtaaatcgataaggatccgtcgaccgatgcccttgagagcttcaaccagtcagct 
ccttccggtggcgcggggcakactatcgtccgccgcmmttatgactkgtcttctttatca 
tgcaacmsgaggamaggtrccgacagcgctattrcgmgttctgcattcatgactgcttgc 
actcgggyagtcgactgcgcgagcggatwcacgtctcwgttaagactgtgt 
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Second Day after transfection 
• 48 hours after start of transfection harvest the cells by trypsinization. 
• Add ~1.7 ml DMEM complete and transfer cells to a 2 ml tube and spin 
5 min. at 300×g. 
 
For FACS samples: 
• Remove supernatant, resuspend cells in PBS. 
• Transfer the cells to a FACS tube and spin 5 min. at 300×g. 
• Remove supernatant and resuspend cells in ~0.5 -1ml PBS. 
• Keep cells on ice. 
• Perform FACS assay. 
 
For the other samples: 
• Remove supernatant as much as possible. 
• Continue with the gDNA isolation or store the cell-pellet at -80ºC. 
 
 
Genomic DNA isolation 
 
Isolate the gDNA with the DNeasy Tissue kit. Follow the ‘DNeasy Protocol for 
Cultured Animal Cells’. 
• Include RNase A in step 1. 
• Elute gDNA in 1×200 µl + 1×100 µl buffer AE in a 2 ml tube. 
• Measure concentration of gDNA. 
 
 
 
 
Ordering information 
 
Lipofectamine 2000  Invitrogen Cat. No.: 11668-027 
Opti-MEM I   Invitrogen Cat. No.: 31985-047 
DNeasy Tissue Kit (50)  Qiagen  Cat. No.: 69504 
RNAse A solution 100 mg/ml Qiagen  Mat. No.: 19101 
Transfection of MCF-7 with Lipofectamine 2000 
(Maartje Vogel version 120903) 
Please check http://www.nki.nl/nkidep/vansteensel for updated versions of 
this protocol. 
 
One day before transfection 
• Harvest cells from exponential phase. 
• Seed 4×105 cells per well (of a 6-well plate) in 2 ml DMEM complete 
medium (10% FCS + antibiotics (e.g pen/strep)).  
• Rock the plate after seeding. 
Cells should be ~90% confluent at the time of transfection. 
 
Day of transfection 
Consider the following (control) transfections: 
 
… x Plasmid(s) encoding the Dam protein 
… x Plasmid(s) encoding the Dam-fusion protein (your protein of interest fused to 
Dam). 
 
Controls: 
1 x pH2B-GFP (to determine the transfection efficienty by FACS). 
2 x no plasmid (control in methylation PCR and neg. control for FACS). 
 
1 x pIND-(V5)-EcoDam and 
1 x pIND-Cbx1-V5-EcoDam (serve as a positive control in the methyl-PCR and hy-
bridizations). 
 
1-2 x pIND (empty vector, serves as a control in the methyl PCR). 
 
• For each transfection sample, prepare in separate 1.5 ml tubes: 
1) 2 µg DNA in 100 µl Opti-MEM-1 (RT). 
2) 6 µl Lipofectamine 2000 in 100 µl Opti-MEM-1 (RT). Mix the 
Lipofectamine gently before use. 
• Incubate 5 min. at RT (proceed to next step within 30 min. after diluting 
the lipofectamine) 
• Combine the two solutions, mix gently and incubate for 20 min. at RT 
(The mixture may appear cloudy). 
• In the mean time: wash the cells with DMEM (w/o serum and antibiot-
ics). 
• After the 20 min. incubation: add 800 µl DMEM (w/o serum and antibi-
otics) to the DNA-Lipofectamine mixture, mix gently and add this to the 
cells. 
• Incubate for 5 hours in a 37ºC incubator. 
• Carefully add 1 ml of DMEM (with 20% FCS, w/o antibiotics) to the 
cells (don’t remove the transfection mixture). 
• Incubate o/n in a 37ºC incubator. 
 
First day after transfection 
• The next morning: replace transfection mixture with DMEM complete 
medium. 
 
Appendix Figure 3: The Maartje Vogel MCF7 Lipofectamine 2000 Transfection Protocol. 
Retrieved from: 
http://genome.cshlp.org/content/suppl/2006/10/12/gr.5391806.DC1/LipofectTransfect_gDNAi
sol_MCF7_060725.pdf 
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For support, visit www.lifetechnologies.com/support.
Lipofectamine® 2000 Reagent Protocol 2013
-2-
Lipofectamine® 2000 DNA Transfection Reagent Protocol
Transfect cells according to the following chart. Volumes are given on a per-well basis. Each reaction mix is sufficient for triplicate (96-well), duplicate (24-well), and 
single well (6-well) transfections, and accounts for pipetting variations. Adjust the amounts of components according to your tissue culture format. For additional 
information on scaling your transfection reaction, see page 1.
Timeline Steps Procedure Details
1
2
3
4
5
6
7
Da
y 
1
Da
y 
2–
4
Da
y 
0
5
Seed cells to be  
70–90% confluent at 
transfection
Component 96-well 24-well 6-well
Adherent cells 1–4 × 104 0.5–2 × 105 0.25–1 × 106
Dilute four amounts of 
Lipofectamine® Reagent in 
Opti-MEM® Medium
Opti-MEM® Medium 25 μL × 4 50 μL × 4 150 μL × 4
Lipofectamine® 2000 
Reagent  1, 1.5, 2, 2.5 μL  2, 3, 4, 5 μL  6, 9, 12, 15 μL
Dilute DNA in Opti-MEM® 
Medium
Opti-MEM® Medium 125 μL 250 μL 700 μL
DNA (0.5–5 μg/μL) 2.5 μg 5 μg 14 μg
Add diluted DNA to diluted 
Lipofectamine® 2000 Reagent 
(1:1 ratio)
Diluted DNA Total 25 μL 50 μL 150 μL
Diluted Lipofectamine® 
2000 Reagent 25 μL 50 μL 150 μL
Incubate Incubate for 5 minutes at room temperature.
Add DNA-lipid complex to 
cells
Component 96-well 24-well 6-well
DNA-lipid complex per 
well 10 μL 50 μL 250 μL
Final DNA used per well 100 ng 500 ng 2500 ng
Final Lipofectamine® 2000 
Reagent used per well 0.2–0.5 μL 1.0–2.5 μL 5.0–12.5 μL
Visualize/analyze  
transfected cells
Incubate cells for 1–3 days at 37°C. Then analyze transfected cells.
Appendix Figure 4: Lipofectamine 2000Transfection Protocol from Life Technologies. 
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  Appendix Figure 5: Sequencing results of pGL3-1.005ARC-GFP(luc-). A) Sequenced using 
the RV3P primer. This only captured the beginning of the 1.005 kB ARC sequence, therefore 
another primer bound to a different site on the plasmid was used for a second round of sequencing. 
B) Sequenced using a primer that bound just before the end of the 1.005 kB ARC sequence and 
captured the end of this sequence and the beginning of GFP.  
ARC promoter region 
 
ggagcagtgcagactttctctatcgataggtaccgagctcttacgcgtgctagcaagggg 
cttggaaccagtccgccgctgcacatccttcttggcttcctggcgccccctatcgggggt 
gagcgaagcccccactactaaatggcctctctccactaccccgactatccctgcacataa 
actccgttttttttttttctgtttctggtctcttttctctatcgaccagggagcacagga 
gttatgggtggggggtgattttgcatttgtagaagcgtccagatactaggtttttaatag 
aggaacccctggagggtggaggtgcttggggatccggtgcctagctcccttgcttaggcc 
cgggtccagggctggcgcggggccgctgcaatctctgggaagcgggggcttctgggtcgc 
gctcagctctgcaatgcatgcgttctgtgatcctggtgagttggtatccttctctgaact 
tcctctgtgacaggcagagaagaggggtcgatgacaagatagatggaaagcacctggaaa 
ttggcaggccctgagtgggcgctggacgtgtggggccgcgggccgaactgccccctcctg 
gcctcatctcctggtgcgccccgggtggggagggaaagctgactacatgcacgtccccag 
ccagcgcgcggcctccgcggtgtggctcctagtgcccggggaagaaccctcaccctccct 
attcccagcagccctggccgccccgcccccgccgcagctgctgcacccacccccaccctg 
cccggccctttctgcaccgtcatctcctgccccgccgaggcttgacccgtgagtggggac 
gcccaaaacgggccagaccgggagccccactcccggctgtgggagggaagggaaaccgag 
attgggcagaatcagcgccccaccacccgctgcgcgctcggggtcggggggggcgggggt 
ggggtaggactgtggacccgccctgcrcakgamctctcaagctctggtactgggtggagg 
gagtaaggrscgggggggaaatcctgcrtcgmactcrgatytgcatctaactarcctgcc 
mcatsgtcarcaayggcgacgagctgtcacgrggtgtkccatcctkgaygaactgacktc 
tactaacggcmcaagatcaccgtccgcttaggctragcatgcactacgcactgacctaag 
gtacctggtacgacgtcaasttgctcgwggtac 
	
ARC promoter region 
HindIII restriction site 
GFP 
 
tttsgackacgtgagtggggmgcccaaacgggccagaccgggagccccactcccggctgt 
gggagggaagggaaaccgagattgggcagaatcagcgccccaccacccgctgcggcgctc 
gggggtcgggggggcggggtgggtaggactgtgggccccgccctgccgcaggactctcaa 
gctctgggactgggtggagggaggtaaggggcggggggggaaaatccgtgcagtcgcacc 
tcgagatctgcgatctaagtaagcttgccaccatggtgagcaagggcgaggagctgttca 
ccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcg 
tgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgca 
ccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgc 
agtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgc 
ccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagaccc 
gcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcg 
acttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccaca 
acgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgcc 
gcaacatcgaggacggcggcgtgcagctcgccgaccactaccagcagaacacccccatcg 
gcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagca 
aagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgcccggg 
atcactctcggcatggacgagctgtacaagtaagcggccgcgacgctagagtcggggcgg 
ccggccgcttcgagcagacatgatagatacattgatgagttgacaaccacactagatgca 
gtgaaaaaatgctttatttgtgaattgtgatgctatggcttaattgtacatatagctgca 
taccagtacacacatgcatcgttagttcagttcaagggagtgtgatgagtttttaaggcc 
agtaac 
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Appendix Figure 6: Sequencing results of pEGFP-N1-1.005ARC(CMV-). 
Since there is no RV3P binding site on the pEGFP-N1 plasmid, the primer 
used to isolate the 1.005 kB ARC sequence from the original pGL3-basic 
plasmid was used for sequencing. This primer bound to the beginning of the 
1.005 kB ARC sequence.  
ARC promoter region 
 
ctcagttactgcmgtctytysttggcttcctggcgccccctatcgggggtgagcgaagcc 
cccactactaaatggcctctctccactaccccgactatccctgcacataaactccgtttt 
ttttttttctgtttctggtctcttttctctatcgaccagggagcacaggagttatgggtg 
gggggtgattttgcatttgtagaagcgtccagatactaggtttttaatagaggaacccct 
ggagggtggaggtgcttggggatccggtgcctagctcccttgcttaggcccgggtccagg 
gctggcgcggggccgctgcaatctctgggaagcgggggcttctgggtcgcgctcagctct 
gcaatgcatgcgttctgtgatcctggtgagttggtatccttctctgaacttcctctgtga 
caggcagagaagaggggtcgatgacaagatagatggaaagcacctggaaattggcaggcc 
ctgagtgggcgctggacgtgtggggccgcgggccgaactgccccctcctggcctcatctc 
ctggtgcgccccgggtggggagggaaagctgactacatgcacgtccccagccagcgcgcg 
gcctccgcggtgtggctcctagtgcccgggraagaacmytcaccctccctattcccagca 
gccctggcygccccrcccycgccgcagctgctgcacccayscccaccctgcccggccctt 
tctgcmccgtwmtytcctgccccgcwkagsyttgacccgmgagtggrgwacgycaaawsg 
ggscagaycgggstccccactccysgctgtggaggkagkgrwaacccasattgwmmrwaa 
wcwmcgccccacmcwrswtmckgcsttagrgmwtmg 
 
 
